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Recently, whole body two-(18F)-fluoro-2-deoxy-D-glucose positron emission 
tomography (FDG-PET) has been established as an important tool in clinical 
oncology. FDG-PET is a non-invasive, functional imaging technique. It is 
clinically used to detect a wide variety of tumours including lymphoma, 
melanoma, lung cancer, pancreatic and colon cancer as well as benign 
disorders such as vasculitis (1-4). 
Earlier retrospective studies showed that FDG-PET also detects 
premalignant gastrointestinal disorders like colonic adenomas (5;6). This 
thesis aimed at studying the possibilities of FDG-PET to detect premalignant 
lesions and early cancers in the digestive tract. We focused mainly on 
colonic adenomas, because focal uptake of FDG is relatively frequent seen 
on FDG-PET in patients studied for other malignancies than colorectal 
cancer and these findings are yet unclear. Secondly, on patients with chronic 
pancreatitis because of their high risk on developing pancreatic cancer and 
the lack of adequate methods to detect cancer in this specific patient 
population. These considerations stimulated us to design some studies in 
which we tried to answer the following questions: does FDG accumulate in 
colonic adenomas, which factors predict the detection of adenomas, is FDG-
PET able to differentiate between chronic pancreatitis (CP) and pancreatic 
carcinoma, can FDG-PET detect pancreatic carcinoma superimposed on CP 
and to determine the value of FDG-PET in familial adenomatous polyposis 
(FAP) patients.  
 
Chapter two deals with the basic principles of FDG-PET and the well-
established indications in gastrointestinal cancers. In current gastrointestinal 
practice, FDG-PET is most commonly used to stage oesophageal cancer, to 
detect and stage recurrence of colorectal cancer and to differentiate 
between benign and malignant pancreatic lesions. 
 
In chapter 3 we describe a N-nitrosobis(2-oxopropyl)amine (BOP) hamster 
model. Hamsters treated with BOP develop pancreatic cancer. This study 
was mainly designed to investigate the dynamics of FDG uptake in 
pancreata developing pancreatic cancer. We speculated that increased FDG 
accumulation precede the onset of pancreatic cancer. 
 
In pancreatic cancer cure can only be achieved by complete surgical 
resection, however only if the tumour is diagnosed in an early stage. Only a 
minority of patients is eligible for surgery, due to the fact that the tumour 
mostly is diagnosed in an advanced phase. The overall survival then 
declines to 4-5 months. Chronic pancreatitis patients have a clearly 
increased risk on pancreatic cancer (7). In this specific population 
diagnosing pancreatic cancer is even more difficult, because CP mimics the 
symptoms and radiological signs of pancreatic cancer.  
Preliminary data suggest that FDG-PET is able to differentiate CP from 
pancreatic cancer, but it is not yet known whether FDG-PET is able to detect 
pancreatic cancer in CP patients (8-18).  
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So, in chapter 4 we focused on the group of patients with CP, we studied the 
diagnostic efficacy of FDG-PET in a large cohort of exclusively CP patients, 
or pancreatic cancer superimposed on CP. We included pancreatic cancer 
patients as a positive control. 
 
FAP is an autosomal dominant inherited disorder and is characterized by the 
development of multiple colonic adenomatous polyps. Furthermore, 58-90% 
of FAP patients develop duodenal adenomas and particularly the patients 
with advanced duodenal adenomas have a high risk for duodenal cancer 
(19-21). Once duodenal carcinoma is diagnosed the prognosis is dismal. In 
case of advanced duodenal adenomas duodenectomy is recommended to 
prevent duodenal cancer. The current screening modalities have their own 
limitations and none of them are sufficient. In chapter 5 we describe the 
diagnostic outcome of FDG-PET in a FAP cohort, especially in patients with 
duodenal adenomas our hypothesis was that FDG-PET detects malignant 
degeneration of duodenal adenomas. 
 
Azoxymethane (AOM) is a potent carcinogen that induces colorectal 
adenomas and cancer in rat and mice, the AOM induced colorectal cancers 
follow the same concept as tumour initiation in human. AOM treated rats 
develop colonic adenomas and carcinomas. The study described in chapter 
6 was designed to correlate FDG uptake to histopathologic changes in AOM 
induced adenomas and carcinomas. We studied in which phase of the 
adenoma-carcinoma sequence FDG accumulation originate. 
 
Colon carcinogenesis is regarded as a multifaceted process and involves a 
histologic progression from adenomatous polyps in colonic cancer (22). 
Colonic cancer originates in most of the times from benign colonic 
adenomas and the most important indicator of outcome after surgical 
resection is the pathologic stage at presentation. Detection and removal of 
colonic adenomas is thought to result in a decrease in incidence and 
mortality of colonic cancer (23). Fecal occult blood test, barium enemas, 
virtual colonoscopy and colonoscopy are used as screening methods to 
detect colonic adenomas. Colonoscopy is regarded as the gold standard. 
FDG-PET has a role in the management of colorectal cancer patients (4;24-
26). Besides, focal uptake in the colon is frequently seen on FDG-PET in 
patients studied for other malignancies than colorectal cancer (CRC). 
Colonoscopy next to FDG-PET did not only show colorectal cancers, but 
also adenomas (5;6). In chapter 7 we present a prospective cohort study in 
which we establish the possibilities of FDG-PET in detecting colonic 
adenomas, using colonoscopy and histology as the gold standard.  
 
Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant inherited 
disorder, the affected patients has a cumulative risk of developing gastric 
cancer of 67-83% by the age of 80 (27). Diffuse gastric cancer evades 
detection by gastroscopy because of lack of tumour mass.  
General introduction and outline of the thesis 
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This eliminates upper endoscopy as an effective screening method, we 
hypothesized that FDG-PET could have a role in detecting early gastric 
cancer in HDGC.  
In the appendix we describe a HDGC patient with early gastric cancer, FDG-
PET detected this early gastric cancer. 
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Abstract 
 
This review deals with the current, well-established, indications for two-(18F)-
fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan-
ning in patients with gastrointestinal cancers. FDG-PET is a non-invasive, 
functional imaging technique. FDG exploits the native glucose transporter to 
enter the cell. Since many tumours have enhanced glucose uptake, FDG is 
readily accumulated in malignant cells and can be detected by a PET 
camera. FDG-PET has been established as an important diagnostic tool in 
clinical oncology. This review deals with the current, well-established, 
indications for FDG-PET scanning in patients with gastro-intestinal cancers. 
In the current practice, FDG-PET is most commonly used to stage 
oesophageal carcinoma, to detect and stage recurrence of colorectal 
carcinoma and to differentiate between benign and malignant pancreatic 
lesions. The benefit of FDG-PET scanning in patients with oesophagus 
carcinoma is best established in stage IV disease, as the diagnostic 
accuracy to detect metastatic disease is higher compared to the combination 
of computed tomography (CT) and endoscopic ultrasound (EUS). In patients 
with a history of colorectal carcinoma, FDG-PET scanning is particularly 
effective in diagnosing recurrent disease, especially in those with a rising 
carcinoembryonic antigen without a suspect lesion on conventional imaging. 
Large series have indicated that the sensitivity and specificity for detecting 
recurrent colorectal carcinoma are in the range of 87-100% and 66-100%, 
respectively. Equally, FDG-PET has a high sensitivity (68-96%) and 
specificity (78-100%) in detecting pancreatic carcinoma in patients with a 
suspicious-looking pancreatic mass on CT scan. Lastly, we focus on the use 
of FDG-PET as a modality for early monitoring of treatment response in 
patients with gastrointestinal stromal cell tumours. Without doubt, future 
developments will further establish the diagnostic role of FDG-PET scan in 
the care of patients with gastrointestinal cancers. 
  
 
Introduction 
 
Gastrointestinal cancers account for a high proportion of newly diagnosed 
tumours and are a major cause of death in Western Europe. In most cases, 
it is possible with the use of conventional radiographical imaging techniques 
to collect sufficiently accurate information about the extent of the primary 
tumour, presence of distant metastases and tumour recurrence. However, all 
current available conventional methods solely rely on the presence of 
anatomical changes induced by the tumour. In the absence of a significant 
mass effect of the tumour, detection is severely thwarted. Two- (18F)-fluoro-
2-deoxy-D-glucose positron emission tomography (FDG-PET) is a non-
invasive, functional imaging technique (1) that differs from conventional 
diagnostic methods because it visualizes the metabolic activity of the tumour 
rather than its anatomical borders. Several studies have suggested that the 
                                                                                    Chapter 2 
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detection of tumoural metabolic activity by FDG-PET probably is a better 
reflection of stage and extent of malignant disease and, as such, it is an 
important novel diagnostic tool in oncology.  
 
Principles of the FDG-PET scan 
 
The most commonly used radiopharmaceutical in human PET scanning is 
FDG, which is a glucose analogue (1). FDG uses glucose transport 
receptors (GLUT-1) to enter the cell. In the same fashion as glucose, FDG, 
is phosphorylated by hexokinase to FDG-6-phosphate. Hexokinase is an 
important enzyme of the glucose metabolism. In contrast to glucose-6-
phosphate, FDG-6-phosphate is not further metabolized and as it cannot 
transfer beyond the cell membrane it is trapped in the cell. In this manner, 
FDG-PET visualizes the glucose metabolism in the human body. Physiologic 
FDG accumulation is seen in tissues with high insulin-dependent cellular 
glucose uptake or with a low cellular glucose-6-phosphatase concentration 
because FDG-6-phosphate cannot be dephosphorylated (2;3). In these 
tissues, such as the cortex of the brain, muscles and myocardium, FDG 
accumulation depends mainly on the glycolytic rate. To limit the physiologic 
uptake of FDG in (activated) muscles, patients are advised to refrain from 
any activity during the distribution phase, the first hour after the FDG 
injection. FDG is excreted by the kidneys into the urine and this might be 
another source of spurious FDG accumulation. To prevent this inadvertent 
accumulation in the collecting ducts, it is important to hydrate the patients 
and give furosemide in order to stimulate frequent voiding of the bladder. 
FDG can also accumulate in the intestine and the stomach but with wide 
inter-individual variation (Fig. 1). 
 
 
 
Figure 1 Normal positron emission tomography (PET) scan after injection of two-
(18F)-fluoro-2-deoxy-D-glucose (FDG) in a healthy volunteer; high accumulation of 
FDG in the brain, myocardium and the bladder. 
FDG-PET scanning in the diagnosis of gastrointestinal cancers 
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Most malignant cells demonstrate high FDG uptake owing to increased 
expression of the GLUT-1 receptor on the cell membrane (1;4-7). In addition, 
a high enzymatic activity of hexokinase and low levels of glucose-6-
phosphatase in tumour cells also account for an elevated FDG uptake. 
Increased FDG uptake is also seen in areas of inflammation, especially in 
infections and granulomatous disorders and can account for false-positive 
results (8). High plasma glucose levels are responsible for false-negative 
FDG-PET scans. 
The FDG-PET scan can be evaluated visually or (semi) quantitatively using 
kinetic modelling, the standardized uptake value (SUV) or a tumour-to-
background ratio. The SUV is the uptake measured in the lesion in 
microcuries per millilitre divided by the weight of the patient in kilogram and 
the injected FDG dose in millicuries. The SUV method gives more quanti-
tative information about the FDG uptake in the lesion. Nevertheless, in daily 
practice visual interpretation of the data is sufficient in most cases. This is 
illustrated by figure 2 showing an FDG-PET scan of a patient with extensive 
metastatic disease.  
Without doubt, FDG-PET has been established as an important tool in 
clinical oncology. The main indications are staging of malignant disease, 
localization of an unknown primary, detecting tumour recurrence, 
differentiation between malignant and benign lesions on conventional 
diagnostics and therapy monitoring. In current gastroenterological practice, 
FDG-PET is most commonly used to stage oesophageal carcinoma, to 
detect and stage recurrence of colorectal carcinoma and to differentiate 
between benign and malignant pancreatic lesions. In addition, it can be used 
as a monitor of efficacy of therapy such as in gastrointestinal stromal cell 
tumours (GISTS). In this article we focus on these most commonly used 
applications of FDG-PET scanning in cancers of the gastrointestinal tract. 
 
 
Figure 2 Coronal section of a whole body 2-(18F)-fluoro-2-deoxy-D-glucose 
positron emission tomography (FDG-PET) scan of a patient with extensive 
liver and bone metastases, in addition to physiologic accumulation in the 
brain, myocardium and the bladder. 
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Oesophageal Carcinoma 
 
Oesophageal cancer is associated with a poor prognosis due to lack of 
symptoms in the early stage of the disease. Consequently, most patients 
present with advanced disease. The five-year survival is clearly dependent 
on the extent of the tumour, being 75% in stage 0, and only 15% in stage III 
and even 0% in stage IV (9). Conventional diagnostic techniques such as CT 
scanning, endoscopic ultrasound (EUS), magnetic resonance imaging  (MRI) 
and ultrasonography of the neck region have a low negative predicting value 
to detect stage IV disease. These tests usually fail to detect distant lymph 
node metastases and liver metastases and consequently have a low 
accuracy to detect unresectable disease (stage IV).  
Oesophageal carcinoma cells have high glucose consumption, and are 
therefore amendable to visualization by FDG-PET scanning. The current 
literature contains nine studies comprising a total of 456 patients that 
examine the diagnostic benefit of the FDG-PET scan in staging oesophagus 
cancer (10-18). The sensitivity of the FDG-PET scan for detecting the pri-
mary tumour is very high and reaches almost 100% (table 1), but FDG-PET 
scanning may miss small T1 oesophageal tumours. On the other hand, 
FDG-PET scanning has a higher accuracy for diagnosing stage IV disease 
compared with the combination of CT and EUS (table 1). FDG-PET 
scanning has important implications for the clinical management of these 
patients, as FDG-PET scan changed the therapeutic plan in almost one-fifth 
of patients. In most instances the stage of the disease was upgraded, 
leading to cancellation of scheduled surgery. On the other hand the FDG-
PET scan had no additional value for locoregional lymph node staging, as 
the resolution does not allow a distinction to be made between FDG uptake 
in the primary tumour and locoregional lymph nodes. In these cases, EUS 
appears to be the most sensitive diagnostic tool for locoregional lymph node 
staging with a sensitivity of around 81% (15). EUS seems also the best tool 
for tumour in-growth in the aorta.  
The semi-quantitative assessment of the tumoural FDG accumulation can be 
used as a prognostic tool. For example, Kato et al. (18) studied the 
correlation between the amount of FDG uptake in the primary tumour in SUV 
in patients operated on for squamous cell oesophagus carcinoma with the T-
classification and the 2-year survival. Patients with a SUV < 3 had a 
significant better 2-year survival than patients with a SUV ≥ 3, 91% vs. 48%. 
They conclude that carcinomas with a high FDG uptake are more aggressive 
and are associated with a poor survival. It is currently under debate whether 
these patients would benefit from neoadjuvant therapy. 
Most patients with locally advanced squamous cell carcinoma have a poor 
outcome, and in an effort to improve outcome, adjuvant chemoradiation 
therapy is being used in combination with surgery. Recently, several study 
groups (19;20) investigated the use of FDG-PET to predict the response to 
neoadjuvant chemoradiation in these patients. 
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    Table 1   Representative studies regarding sensitivity of primary tumour stage and stage IV disease of FDG-PET in oesophagus     
    carcinoma.  
           
Stage IV disease 
 
 
         CT    PET 
 
 
   Author  Patient   Primary tumour  Sens. Spec. Acc.  Sens. Spec.  Acc. 
   (reference)  (no.)  Sensitivity (%)                         (%)    (%) 
 
    Block (10)  58  97                              29     100 
    Flanangan (11) 36  100   0  96*  78*   71* 100*  94* 
    Kole (12)                  26                    96   67*  95*  88*   100 90* 92* 
    Rankin (13)              25                 100                                
    Luketich (14)          91                   97#               46    73       63                    69    93   84 
    Flamen (15)             74                    95                              41     83        64       74     90    82 
    Skehan (16)             61                91                                                                  100#  91# 
    Kim (17)                   53                    96 
    Kato (18)                  32                    78        
  
 
   CT= computed tomography; PET = positron emission tomography; Sens.= sensitivity; Spec= specificity; Acc.= accuracy;  
    * calculated data;  # percentage of a subgroup  
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Brücher et al. (19) showed that a decrease in SUV of 50% (denoting a 
response) after chemoradiation therapy is associated with a good 
histopathologic response, with a sensitivity of 100% and a specificity of 55%. 
They also showed that non-responders had a significantly poorer prognosis.  
Other researchers investigated the change in FDG uptake in the tumour 
before and 14 days after start of chemotherapy (21). Reduction of tumour 
FDG uptake of at least 35% (metabolic responder) predicts a clinical 
response with a sensitivity of 93% and a specificity of 95%. Non-responders 
have significantly shorter time to progression and shorter survival. 
It appears that, FDG-PET is able to identify those patients that benefit from 
adjuvant chemoradiation therapy, but larger, prospective studies are clearly 
necessary to establish the actual place of FDG-PET scanning in 
neoadjuvant therapy of oesophageal carcinoma. 
 
 
Colorectal Carcinoma 
 
Colorectal cancer (CRC) is very common and in 1998 alone some 131,600 
new cases in the United States were diagnosed. The prognosis is dismal as 
in 1998 56,500 US patients died of CRC (22). It is estimated that some 70% 
of the patients undergo potentially curative surgery, but there is a high rate 
of recurrence in the range of about 40% within 2 years. Some 10% of 
patients have isolated liver metastases at first presentation (23). It is 
imperative to strive for an early detection of CRC recurrence. In clinical 
practice, carcinoembryonic antigen (CEA) is used to identify CRC recurrence 
and a rising CEA has a sensitivity of 60-70% and a specificity of 84% to 
detect recurrence (24). After detection of a rise in CEA, the patient is usually 
scheduled for CT scanning, but this fails to demonstrate hepatic metastases 
in about 7% (25). Furthermore, metastases to the peritoneum, mesentery 
and lymph nodes are commonly missed on CT. Sensitivity is further 
hampered by the fact that CT cannot differentiate between post-surgical 
changes and local recurrence. In addition, it is eminently important to identify 
those patients with recurrent CRC that benefit the most from surgery and 
there is certainly room for improvement here. For example, some 30% of 
patients with recurrent CRC disease seem to have limited disease as judged 
by conventional radiological techniques, but a majority of these patients still 
does have extensive disease (26). Therefore, to prevent unnecessary 
surgery it is important to improve preoperative staging. FDG-PET scanning 
appears to fill some of the gaps that are inherent with conventional 
techniques. 
Huebner et al. (27) published a meta-analysis about the use of the FDG-PET 
scan in detection of recurrent colorectal cancer (table 2). They collected 11 
studies comprising a total of 570 patients (28-38).  They determined an 
overall sensitivity of 97% (95% confidence level 95-99%) and an overall 
specificity of 76% (95% confidence level 64-88%) for FDG-PET to detect 
recurrence. Seven articles (29-32;34;37;38) reported data restricted to liver 
FDG-PET scanning in the diagnosis of gastrointestinal cancers 
 
24 
CRC, with a total of 393 patients, sensitivity and specificity were 96% and 
99%, respectively. Local and/or pelvic recurrence was investigated in 5 
studies, with a total of 366 patients, and sensitivity and specificity were 95% 
and 98%, respectively. The calculated change in management was 29% 
(95% confidence level 25-34%), however only 7 (28;30-32;34;37;38) studies 
included data on change in clinical management. The impact of the FDG-
PET scan on therapeutic management in recurrent CRC was confirmed by 
Kalff et al. (39). In a prospective study they found that FDG-PET scanning 
had a direct influence on clinical management in 59% of 102 patients with 
recurrent CRC. This is in line with another study where the investigators 
found a major change in management in 48% and a minor change in 3% 
(40). In a prospective study, a change in therapeutic management was 
demonstrated in 29% of patients with liver metastases of CRC (41). In 
another study of patients with metastatic or recurrent colorectal cancer, 
FDG-PET scanning affected the therapeutic plan in 40% of the 42 patients 
deemed potentially resectable after conventional radiological diagnostics 
(42).  
Park et al. published a study in which they used a decision tree to evaluate 
the cost-effectiveness of the FDG-PET scan plus CT strategy compared to 
CT alone in recurrent CRC (43). They showed that the FDG-PET plus CT 
strategy was more expensive, but resulted in an increase in the mean life 
expectancy of 9.5 days per patient. This gain in life expectancy was possibly 
based on improved diagnosing and staging but also due to the cancellation 
of a, potentially lethal, invasive surgical procedure. 
Some studies have investigated the utility of the FDG-PET scan in predicting 
response to therapy or predicting prognosis, but there is a paucity of large 
prospective studies. Oku et al. showed a decrease in SUV after radiation 
therapy in patients with rectal cancer (44). There was a significant difference 
in SUV after radiation therapy between the groups with and without 
recurrence. Another study in patients treated with chemotherapy 
(fluorouracil, folinic acid and oxaliplatin) for metastatic CRC, found that pre-
treatment dynamic FDG-PET scan accurately predicts therapy outcome in 
90% of patients with progressive disease and in 60% of patients with stable 
disease, but only in 10% of patients with partial response after chemo-
therapy (45).  
In conclusion, the main indications, according to the present literature, for a 
FDG-PET scan in CRC are; 1) rising CEA without a focus on conventional 
imaging, 2) differentiation between fibrosis and a locoregional recurrence, 
and 3) preoperative staging in potentially resectable recurrent disease. FDG-
PET has no additional value in staging primary CRC, because the lack of 
anatomical detail prevents accurate determination of the degree of local 
invasion (46). 
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Table 2  Adapted from a meta-analysis by Huebner et al. (27): sensitivity, specificity, and change in management owing to FDG-PET 
in recurrent colorectal cancer. 
 
Author (Reference no.)  Patients (no.)  Sensitivity  Specificity  Change in management 
 
 
Beets (28)      35         40% 
Schiepers (29)     76   96%   97%                       
Vitola (30)    24   95%   80%   25% 
Lai (31) 34   100%          67%   29% 
Delbeke (32) 61   98%          83%   33% 
Keogan (33) 18   92%          80% 
Ogunbiyi (34) 47   90%          100%   44% 
Ruhlmann (35) 59   100%          69%    
Flanagan (36) 22   100%          71%    
Valk (37) 115   95%          79%   31% 
Flamen (38) 103   94%   100%   20%   
 
FDG-PET = 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography.    
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Pancreatic carcinoma 
Among gastrointestinal cancers, pancreatic carcinoma is associated with the 
worst prognosis. Although 5-year survival is dependent on the extent of the 
tumour, it is only 8% in localized disease and 1.5% in advanced disease. 
One of the main reasons for poor survival is that pancreatic carcinoma 
escapes detection until a very late stage when patients become symp-
tomatic. In localized disease, surgery is the therapy of choice but in 
advanced disease, palliation is the only option. This emphasizes the need 
for early and reliable detection of pancreatic carcinoma. Patients with 
chronic pancreatitis are at risk of developing pancreatic carcinoma, and the 
risk is very high (lifetime risk 20% by the age of 60 years and 40% by the 
age of 70 years) in those with a hereditary form of pancreatitis (47). 
Differentiation between mass-forming chronic pancreatitis (CP) and 
pancreatic carcinoma is very difficult or almost impossible with conventional 
radio diagnostic methods. Measurement of blood CA19.9 level or tissue anti-
p53-autoantbodies and K-ras antigen in duodenal fluid have also a low 
sensitivity and specificity to differentiate CP from carcinoma (48-52).  
Likewise, fine needle aspiration of the tumour has a high false-negative rate. 
However, it is important to differentiate both diseases because of the 
different management and prognosis. FDG-PET scanning has found to be 
helpful in differentiating carcinoma from CP because of overexpression of 
glucose transport and glycolytic enzymes in carcinoma cells (53-55).  
Indeed, the diagnostic ability of FDG-PET scanning to differentiate between 
chronic pancreatitis and pancreatic carcinoma with FDG-PET has been 
subject of a large sample of studies (Table 3). The sensitivity for FDG-PET 
for the diagnosis of pancreatic carcinoma in patients presenting with a 
pancreatic mass, varies between 68% and 100% and the specificity between 
65% and 100% (56-67).  In total, these studies examined 1101 patients. Most 
of the false-positive scans were seen in patients with acute or chronic 
pancreatitis. Another potential confounder is diabetes mellitus. In patients 
with elevated serum glucose (> 130 mg/dl; 6.4 mmol/l), the sensitivity 
declined to 42%, but those results were not confirmed by another study 
(56;67). In addition, correction of serum glucose, by administration of insulin, 
did not significantly improve the diagnostic accuracy of the FDG-PET scan 
(68). 
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Table 3 Sensitivity and specificity of FDG-PET for diagnosis of pancreatic 
carcinoma in patients with pancreatic lesions. 
 
Author (Reference no.)  Patients (n) Sensitivity Specificity  
                                                                   
 
Friess  (56)   80  94%  88% 
Inokuma (57)    46  94%  82%  
Stollfuss (58)    73  95%  90% 
Zimny (59)   106  85%  84% 
Rose (60)   65  92%  65% 
Frohlich (61)   168  68%  95%  
Imdahl (62)   48  96%  100%  
Diederichs (63)   304  81%  83%  
Nakamoto (64)   47  96%  75% 
Koyama (65)   86  82%  81% 
Sperti (66)   56  94%  97% 
Papos (67)   22  100%  88% 
 
 
FDG-PET = 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography. 
 
Addition of FDG-PET scanning in the diagnostic work-up of patients with 
suspected pancreatic cancer does affect the clinical management in 43% of 
cases. In general, FDG PET is more accurate than CT in the detection of 
primary tumours and in the clarification and identification of hepatic and 
distant metastases (69).  
FDG-PET scan is able to detect liver metastases > 1 cm with a sensitivity of 
97% and a specificity of 95%, but the sensitivity drops with very small (< 1 
cm) lesions (43%), although the specificity remains uncompromised (61). 
One study showed that delayed FDG-PET scanning, 2 hours post injection 
of FDG, leads to a higher diagnostic yield. The diagnostic accuracy actually 
rises from 83% in the first scan to 91.5% after delayed scanning. This is 
based on the fact that SUV will rise from 1 to 2 hours after FDG injection in 
patients with carcinoma, whereas SUV will fall in benign disease. These data 
suggest that an additional scan 2 hours after FDG injection is beneficial for 
patients in whom the first scan is inconclusive (62;64). Another study found 
that dynamic scanning is superior to semi-quantitative analysis in 
differentiation between pancreatic cancer and CP (70). SUV is an important 
prognostic marker as it is negatively correlated with survival, and as such it 
has been shown to be an independent prognostic factor in a multivariate 
analysis (71). Patients with a SUV < 6.1 had a significantly better survival 
than patients with a SUV ≥ 6.1, although in another study it could not be 
confirmed to this extent (72). A small study in pancreatic carcinoma patients 
who received chemotherapy showed that absence of FDG uptake one 
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month after chemotherapy is correlated with improved survival (73). Clearly, 
larger prospective studies are warranted to confirm this finding and to 
determine the exact place of the FDG-PET scan for this indication. 
 
 
Gastrointestinal  Stromal Cell Tumours (GISTs) 
 
GISTs represent a distinctive subgroup of gastrointestinal soft tissue 
sarcomas and are the most common mesenchymal tumours of the 
gastrointestinal tract; aetiology and risk factors remain undetermined. GISTs 
predominantly occur in middle-aged and older persons, with an equal male-
female distribution. They arise predominantly in the stomach (50-70%) or 
proximal part of the small bowel (20-30%), though they may be found in any 
other gastrointestinal tract site. Although rare, with an incidence of 
2/100,000, GISTs are of clinical relevance because in at least 10-30% of 
cases they invade adjacent structures and/or metastasize (74). GISTs are 
molecularly characterized by a mutation in the C-Kit gene  
and overexpression of the tyrosine kinase receptor, histopathologically by 
expression of CD34 and/or CD117 proteins. Surgery is the first choice of 
treatment (75;76).  Inoperable malignant GISTs are difficult to treat, and 
many therapy regimens consisting of chemotherapy and/or radiotherapy 
have proven ineffective. A new molecular drug, imatinib mesylate (ST1571), 
which inhibits tyrosine kinase, is a promising systemic therapy for advanced 
GIST (75-79).  
Since GISTs, like many other malignancies, have enhanced glucose meta-
bolism, trials have been conducted to assess response to imatinib mesylate 
treatment with FDG-PET. The GIST collaborative PET Study Group found 
that a PET scan 24 hours after start of imatinib reveals a response, and is 
able to predict unresponsiveness to the drug (80). The very early and strong 
decrease of FDG accumulation after the start of imatinib is attributed to the 
direct inhibition of hexokinase, which is a crucial enzyme for FDG 
accumulation in tumours. In a study of 36 patients, a stable or partial 
response as judged on CT scan was associated in 89% with a decrease in 
FDG uptake of ≥ 50% (81). In a third study of 16 patients, a decrease in FDG 
uptake was reported in the patients after treatment with imatinib (82). There 
are indications that FDG-PET can guide adequate dosing of the imatinib. 
Recent case reports showed an almost normalization of the FDG-PET scan 
after imatinib treatment in GIST patients (83;84). All these studies suggest 
FDG-PET as a useful imaging modality for the early monitoring of therapy 
response in GIST patients treated with imatinib.  
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Conclusion 
 
FDG-PET scanning is a novel imaging technique, which is based on the 
glucose metabolism of the human cells. Malignant cells show higher glucose 
consumption than other cells. The FDG-PET scan is useful in staging 
primary eosophageal cancer, detecting and staging recurrent colorectal can-
cer and differentiating between CP and pancreatic carcinoma. Since false-
positive scans are seen in areas of inflammation, histology is important to 
confirm a positive scan. High plasma glucose levels, especially relevant in 
patients with pancreatic carcinoma, and very small tumours can lead to a 
false-negative scan.  
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Abstract 
 
Background: The prognosis of pancreatic cancer (PC) is highly dependent 
on the stage of the disease, and early recognition improves survival. 
Positron emission tomography (PET) using 18F-fluoro-2-deoxyglucose 
([18F]FDG) has been established as an important clinical tool for PC 
diagnosis, but it is not known whether FDG-PET detects premalignant 
stages of PC. We speculate that [18F]FDG uptake precedes the onset of PC 
in a hamster model. We used the N-nitrosobis(2-oxopropyl)amine (BOP) 
model, as these animals consistently develop PC within 20 weeks after first 
injection.  
Methods: Male Syrian hamsters were injected once a week with 10 mg 
BOP/kg body weight for 10 consecutive weeks. Terminal autopsy took place 
in groups of five hamsters from 4 weeks until 28 weeks after first BOP 
injection. After an 8-hour fast, hamsters were injected with [18F]FDG and 
sacrificed 1 hour after [18F]FDG injection. The pancreata were histo-
pathologically examined, and the [18F]FDG uptake was determined and 
expressed as percentage of the injected dose per gram tissue (%ID/g). 
Results: Seven of 55 hamsters developed macroscopic signs of tumour. 
Histopathological examination revealed PC in 13 hamsters. [18F]FDG uptake 
increased gradually with time and was significantly higher in the group with 
PC compared to the group without PC.  
Conclusion: [18F]FDG accumulates preferentially in PC, and pancreata 
exposed to BOP showed a gradual increase in [18F]FDG accumulation. 
 
 
Introduction 
 
Pancreatic carcinoma (PC) ranks as the eighth most frequent type of solid 
tumour worldwide. The severity of the disease is reflected by the fact that it 
represents the fourth most frequent cause of death (1). Pancreatic 
carcinoma arises from ductular cells, and risk factors involve smoking and 
long-standing chronic pancreatitis. Pancreatic carcinoma can be extremely 
difficult to diagnose in early stages as there are no, or only few, associated 
symptoms. Even in cases with a high clinical suspicion for PC, early 
diagnosis can be difficult despite the availability of diagnostic methods such 
as ultrasound, computed tomography or endoscopic retrograde cholangio-
pancreaticography. Cure can only be achieved by complete surgical re-
section of PC, preferably at an early stage. At later stages of the disease, 
the tumour invades the surrounding tissues, and curative surgery becomes 
an unrealistic goal. Unfortunately, most patients are diagnosed at an 
incurable phase and in those cases the prognosis is bleak, with an overall 5-
year survival rate of < 4% and an average survival between 4–5 months (2). 
Given the fact that the prognosis is highly dependent on the stage of the 
disease, a simple and reliable screening method, especially in high-risk 
populations, would be of tremendous advantage. 
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As it is well known that most malignant cells demonstrate a high glucose 
uptake because of increased glycolysis, this opens an avenue for a new 
screening tool: 2-[18F-]fluoro-2-deoxyglucose-positron emission tomography 
(FDG-PET) (3-7). In clinical practice, FDG-PET scanning is used for staging 
of tumours, detection of tumour recurrence, monitoring of efficacy of therapy 
and for the differentiation between malignant and nonmalignant tissue. FDG-
PET has acquired its place in the diagnostic workup of PC, and it is regarded 
to be more accurate than CT in the detection of primary tumours and in the 
clarification and identification of hepatic and distant metastases (8-14). 
However, most series on the diagnostic accuracy of FDG-PET included 
patients with advanced disease. At this point it is largely unknown at what 
stage [18F]FDG accumulation occurs in the development of PC and whether 
it could be helpful in detecting patients with early disease. We speculated 
that increased uptake of [18F]FDG will precede the onset of PC in a well-
established animal model of pancreatic carcinogenesis. 
 
 
Material and method 
 
Experimental model 
Because of the apparent similarity of the induced tumours to those occurring 
in humans, the N-nitrosobis(2-oxopropyl)amine (BOP) hamster model for  
pancreatic carcinogenesis was used (15;16). These animals developed 
ductular proliferation with dysplasia and pancreatic cancer within 4 months 
after start of BOP treatment. Sixty male weanling Syrian gold hamsters were 
obtained from Harlan (Horst, The Netherlands). Animals were kept on 
softwood bedding in macrolon cages, two or three per cage, under standard 
laboratory conditions. The hamsters were fed the Institute’s stock diet for 
hamsters. N-nitrosobis(2-oxopropyl)amine (Nacali Tesque, Kyoto, Japan) 
was dissolved freshly in 0.9% NaCl solution. The hamsters were injected 
weekly for 10 consecutive weeks subcutaneously with 10 mg BOP/kg body 
weight from the age of 7 weeks onwards. A control group (group 1; n=5) was 
injected with saline. The general condition and behaviour of the animals 
were checked daily. Hamsters were asphyxiated in groups of five at, 
respectively 4, 8, 12, 14, 16, 18, 20, 22, 24, 26 and 28 weeks after the first 
BOP injection. The experiment was reviewed and approved by the local 
animal welfare committee according to the Dutch governmental guidelines. 
 
[18F]FDG accumulation 
[18F]FDG was obtained from Tyco Mallinckrodt Medical (Petten, The 
Netherlands). Specific activity was higher than 1 GBq/µmol, and 
radiochemical purity was always higher than 97% (end of synthesis). 
After a 6-hour fast, hamsters were anaesthetized with isoflurane/ O2/N2O 
and injected intravenously with 3.7 MBq [18F]FDG. One hour after [18F]FDG 
injection the hamsters were sacrificed by CO2 suffocation.  
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A blood sample was obtained by cardiac puncture, and the animals were 
examined for gross pathological changes. Parts of the lung, liver, kidney, 
muscle, spleen and small bowel were excised and weighed, and [18F]FDG 
activity was measured in a shielded well-type gamma counter (Wizard, 
Pharmacia-LKB, Uppsala, Sweden). [18F]FDG uptake was expressed as 
percentage of the injected dose per gram tissue (%ID/g). The entire 
pancreas was excised from each animal and fixed in 4% buffered formalin, 
and their [18F]FDG accumulation was measured, as described above.  
 
Histopathology of pancreas 
Subsequently, excised pancreata were processed for microscopy by 
conventional methods, stained with haematoxylin and eosin (H&E) and 
examined by light microscopy (17). N-nitrosobis(2-oxopropyl)amine induces 
both ductal and acinary changes, and these were scored separately. 
Preneoplastic ductular and ductal lesions were evaluated as described 
previously (15).   
Briefly, intraductal atypical hyperplasia was defined as epithelium of the duct 
composed of more than one cell layer thick with polymorphic nuclei. We 
scored dysplasia as follows: “moderate dysplasia” was defined as the 
increase of apoptosis and mitosis; “severe dysplasia” is characterized by the 
presence of severe atypical nuclei with nucleoli. N-nitrosobis(2-oxo-
propyl)amine also results in ductal complexes (ductal metaplasia of the 
acinus) (18), and we gave particular attention to ductal complexes showing 
dysplastic changes suggestive of progression to malignancy. Again, we 
scored the highest grade of dysplasia from each pancreas and classified it 
as “moderate dysplasia” or “severe dysplasia”. We defined ductular 
adenocarcinoma as a lesion mainly composed of atypical dysplastic ductules 
with invasive growth. Those lesions are most characteristically accompanied 
by an inflammatory response. In case local invasion in the surrounding 
acinar and fibrous tissue was absent, it was classified as carcinoma in situ. 
In addition, atrophy was quantified.  
 
Statistical analysis 
The paired nonparametric Wilcoxon signed rank test was used for statistical 
comparison of values obtained in hamsters with PC versus hamsters without 
PC. The unpaired nonparametric Mann-Whitney U test was used where 
appropriate. Probability ( P ) values were calculated on the basis of two-
tailed tests; correlation coefficient was calculated with the Pearson’s 
correlation test. A P value of less than .05 was considered to be the lowest 
level of significance. Data are given in mean ± S.D. 
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Results 
 
Macroscopic examination 
Macroscopic examination revealed a single PC in four hamsters first 
appearing 20 weeks after first BOP treatment. The pancreas from two other 
hamsters contained two tumours. All other pancreata were free of tumour, 
and we observed no other gross macroscopic changes. 
 
 
 
Table 1 Different histopathological changes per group of five hamsters in 
weeks after first BOP injection.   
 
 
8 12 16 18 20 22 24 
 
Duct abnormality 
  Hyperplasia   + + + + + + + 
  Moderate dysplasia    + + + + + 
  Severe dysplasia     + + + + 
  CIS         +   + 
  Carcinoma                                                                                            +       
 
Ductal complex 
  Early ductal complex   + ++ ++  + + + + 
  Moderate dysplasia     +  + + +       + 
  Severe dysplasia      + + +       +                       
  CIS       + + + + 
  Carcinoma      + + ++     ++ 
 
Atrophy      + + ++ ++ +++       
 
The different stages of carcinogenesis were scored from the moment they first 
appeared in the pancreas. 
CIS, carcinoma in situ;   +, in few hamsters present; ++, in most hamsters present; 
+++, in almost all hamsters present. 
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Histological examination   
Table I summarizes the histopathological abnormalities. 
The first group of five animals, dissected after 4 weeks of BOP treatment, 
failed to show histological abnormalities in the pancreas (Figure 1A). After 8 
weeks of BOP treatment, the lining epithelium of the duct became 
multilayered and the nuclei became polymorphic (atypical hyperplasia). We 
observed early ductal complexes originating from the exocrine-endocrine 
border (Figure 1B), and most of them were cystic. In the following weeks, 
ductal complexes became more pronounced but showed no atypical nuclei. 
At 16 weeks after first BOP treatment, the ductal epithelium became 
moderately dysplastic. We observed that a single duct could show different 
stages of dysplasia, from total normal lining epithelium to moderate 
dysplasia (Figure 1C). Atypia and atrophy arise from ductal complexes. 
From 18 weeks after first BOP injection, we noted the first ductular car-
cinoma (arising in the ductal complexes). At this stage, ductal epithelium 
was characterized by papillomatosis and atypical hyperplasia, and moderate 
to severe dysplasia. From 18 weeks after first BOP treatment, several (n=13) 
pancreata contained one or more carcinomas (Figure 1D). There was severe 
atrophy with pancreatic acinar cells replaced by fat (Figure 1E). The 
pancreatic histopathology was very consistent at this stage, with little 
variation within groups. 
Most carcinomas arose from the ductal complexes, although we observed 
papillary carcinoma arising from the lining epithelium of the duct. This was 
seen in a single animal, 26 weeks after BOP treatment (Figure 1F). In a few 
pancreata, a minor inflammation infiltrate consisting of lymphocytes and 
eosinophils was observed.  
Moreover, desmoplasia was observed only in tumour containing pancreata, 
whereas it was absent in pancreata without cancer.    
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  Figure 1 Panel consisting of six figures (A-F). 
 
A 
 
  B 
 
 
C  D   
E  F    
 (A) H&E x400: normal pancreatic duct surrounded by exocrine acini 
 (B) H&E x400: developing ductal complex at the border (arrow) of the endocrine and    
 exocrine pancreas. No atypia. 
 (C) H&E x200: pancreatic duct with transition of normal (*) to dysplasia () to       
  papillary growth with atypia (4). Arrow points mitosis. 
 (D) H&E x400: invasive growth of moderately differentiated adenocarcinoma with  
  desmoplastic reaction. 
 (E) H&E x50: extensive atrophy of the exocrine pancreas with replacement by fatty  
 tissue. Note the remaining ducts. 
 (F) H&E x100: pancreatic duct showing dysplasia, intra-epithelial carcinoma    
 (cribriform growth pattern) and focal invasive growth (arrow). 
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[18F]FDG uptake 
Figure 2 shows pancreatic [18F]FDG  accumulation, as percentage of 
injected dose per g tissue (%ID/g). The mean value per group of 5 hamsters 
is shown in 2-week intervals. A linear regression analysis shows a significant 
increase in [18F]FDG  uptake in relation to time after BOP treatment. The 
correlation coefficient (r2), as a measure of goodness-of-fit of linear 
regression analysis, is 0.24 (p=0.003). The increase of [18F]FDG uptake 
preceded the onset of histopathological evidence of PC, the pancreata with 
carcinoma show significantly higher [18F]FDG uptake. The [18F]FDG ac-
cumulation was significantly higher (p=0.0014) in pancreata with histo-
pathological evidence of cancer (0.45 ± 0.17 %ID/g, N=13) compared to 
pancreata without cancer, which were harvested at the same time (0.30 ± 
0.08 %ID/g, N=42). [18F]FDG uptake in all other organs was low and did not 
change after BOP injections, including muscle [18F]FDG uptake which was 
included as a control (figure 2). As stated above, a few pancreata showed 
minor inflammation infiltrate consisting of lymphocytes and eosinophils. 
However, this was not associated with significantly increased [18F]FDG 
uptake. It is unknown to what extent the inflammatory component of 
desmoplasia contributed to increased [18F]FDG uptake in malignant tumours. 
However, considering the low grade of this inflammatory reaction, in contrast 
to the large tumour cells, it is tempting to speculate that [18F]FDG uptake is 
mainly due to uptake by tumour cells.  
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Figure 2 The relative 
[18F]FDG accumulation 
(%ID/g) in the pancreas 
and the muscle 
(“background”) as mean 
and standard deviation per 
group of five hamsters per 
2-week time point. The X-
axis refers to the number of 
weeks after the first BOP 
injection. There was a 
significant correlation 
between [18F]FDG 
accumulation in the 
pancreas and time after 
BOP injection (the line is a 
polynominal regression and 
is depicted in the figure as 
a best-fit line) (A). [18F]FDG 
accumulation in individual 
pancreata which were 
histologically scored either 
as severe dysplasia or 
carcinoma (B). 
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Discussion 
 
Our study showed that BOP induces PC as early as 18 weeks after the start 
of treatment. Most carcinomas arose from acinary ductal complexes and 
only one carcinoma originated from the lining epithelium of the duct. We 
hypothesized that increased accumulation of [18F]FDG preceded the onset of 
PC. Our results indicate that there is a significant increase in [18F]FDG 
uptake with time, preferentially in hamsters with PC. However, we observed 
a decrease in [18F]FDG uptake in the last study group compared to the 
prceding group. This corresponded to a major loss of pancreatic acinar cells 
and resulting in acinary atrophy. Notably, only two small carcinomas were 
found in those five animals. It is likely that the drop in [18F]FDG accumulation 
at this time point is caused by the combination of atrophy and the small 
carcinomas.  
There are different hypothesis on the origin of BOP-induced ductular 
complexes. One study showed that the first step in pancreatic 
carcinogenesis is dedifferentiation of acinar cells to duct-like cells, followed 
finally by proliferation of these dedifferentiated acinar cells to pancreatic 
adenocarcinoma (18).  Another study did not confirm this observation, and it 
demonstrated that the pseudoductular lesions originate from proliferating 
ductal/ductular cells rather than from dedifferentiated acinar cells (19). In our 
study, the ductal complexes originate from precursors of acinar cells, like 
described before (18).  However, we showed that BOP is toxic for both 
acinar cells as well as the ductal lining epithelium. N-nitrosobis(2-
oxopropyl)amine results in early ductal complexes with atypia followed by 
PC. After 28 weeks since the beginning of treatment, ductal complexes 
consisted only of extreme atrophy and carcinomas. The second toxic effect 
of BOP is exerted on the ductal lining epithelium with initial hyperplasia 
followed by dysplastic changes. This pattern occurs rapidly after the start of 
BOP treatment, but progression to carcinoma was slow, and occurred only 
incidentally. Most ducts showed hyperplastic and dysplastic changes at the 
same time.   
In clinical literature, most pancreatic PET studies focused on differentiation 
between PC and CP (8;9;11-14;20). Both diseases can present with a 
similar pancreatic mass and irregularities. Consequently, differentiation with 
conventional radiodiagnostics is very difficult. However, differentiation is 
important because of different management, treatment options and 
prognosis. Most imaging studies demonstrated a significant higher [18F]FDG 
uptake in PC compared to CP. There is paucity in studies that focus on FDG 
uptake in early PC or premalignant pancreatic changes, e.g. dysplasia in 
CP. From a screening standpoint this would be most interesting, in particular 
long-standing CP, because those patients have a high risk for malignant 
degeneration of their CP (21).  The main reason to perform our study was to 
investigate the dynamics of [18F]FDG accumulation in PC carcinogenesis. 
Here, we show that [18F]FDG  preferentially accumulates in pancreata 
affected with PC. In contrast, the uptake in nontarget tissues remained 
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constant, underscoring the sensitivity of the [18F]FDG accumulation. Our 
data indicate that the accumulation of [18F]FDG developed gradually, which 
suggests that there is a window of opportunity in the development from 
dysplasia to florid PC during which detection by FDG-PET may be possible. 
These data suggest that the moment of detection of pancreatic abnormalities 
associated with PC can be done at the premalignant, dysplasia stage. This 
creates new opportunities for early diagnosis of PC and screening of high-
risk groups. The question still remains what initiates the [18F]FDG 
accumulation in (pre)malignant pancreatic abnormalities. 
 
 
Conclusion 
 
N-nitrosobis(2-oxopropyl)amine treatment results in ductular adeno- 
carcinoma in the pancreas of the hamster, and these tumours originate 
mostly in acinar cells. [18F]FDG accumulation precedes the onset of PC and 
occurs preferentially in hamsters with PC. 
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Abstract 
 
Purpose: 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography 
(FDG-PET) is an imaging technique which enables detection of 
malignancies. FDG-PET has been established as a tool for diagnosis of 
pancreatic carcinoma (CA). Early detection is mandatory as cure can only be 
achieved in non-advanced disease. This is, however, very difficult with 
conventional radiological techniques. Patients with chronic pancreatitis (CP) 
are at risk of developing CA. A simple, reliable screening method for 
malignant degeneration is highly desirable. We set out to investigate 
whether FDG-PET is able to detect CA in the setting of CP and can fulfil a 
potential role in the early detection of CA in CP. 
Methods: FDG-PET was performed in 77 CP patients and in six patients with 
CP complicated by CA (CP + CA). We included 26 CA patients as a positive 
control. A positive scan was defined as focal FDG accumulation in the 
pancreas region.  
Results: In 67 of the 77 CP (87%) patients, pancreatic FDG accumulation 
was absent. Six patients had significant accumulation. In CA, 24/26 patients 
had a positive PET. Five out of the six patients with CP + CA had focal 
uptake, while minor uptake was seen in one patient. FDG-PET was positive 
in almost all CA patients and CP + CA patients. FDG-PET was negative in 
the large majority (87%) of CP patients, which suggests that a positive PET 
scan in CP patients must lead to efforts to exclude a malignancy. 
Conclusion: These data suggest that FDG-PET has a potential role as a 
diagnostic tool for detecting CA in longstanding CP.  
 
 
Introduction 
 
Chronic pancreatitis (CP) is an ongoing inflammatory disease which can 
lead to destruction of the pancreas with exocrine and/or endocrine functional 
loss (1-4). Although etiological factors such as heredity, anatomical 
variations, and various metabolic disorders play a role, alcohol abuse is 
considered a major contributing factor in most cases (5). Patients with CP 
are at risk for the development of pancreatic carcinoma (CA), and the risk is 
especially high (lifetime risk 20% by the age of 60 years and 40% by the age 
of 70 years) in patients with a hereditary form of pancreatitis (6;7). Current 
radiological techniques, such as computed tomography (CT), often fail to 
differentiate between CP and CA because both can present with similar 
mass-forming irregularities of the pancreas. In CP patients who are 
suspected of having CA, interpretation of a pancreatic mass is even more 
troublesome. The clinician has access to several tools that might help to 
differentiate between CP and CA, such as the history and present symptoms 
of the patient, measurement of the blood CA 19.9 level or tissue anti-p53 
autoantibodies and K-ras antigen detection in duodenal fluid, but all tests are 
hampered by a low sensitivity and specificity (8-12). Measurement of tissue 
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polypeptide-specific antigen (TPS) in serum seems promising, but larger 
studies are required before its implementation in clinical practice will be 
possible (13). Pathological examination of fine-needle aspirates of 
suspected pancreatic tissue is a further technique with a high false-negative 
rate. Apart from its limited diagnostic accuracy, the latter technique is 
invasive and entails an inherent risk of complications. Accurate 
differentiation is of paramount importance, given the markedly different 
management and prognosis of these two disorders.   
Preliminary data suggest that 2-(18F)-fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET) might differentiate CP from CA, but it is 
unknown whether this modality can detect CA in the setting of CP since 
active inflammation might also lead to false-positive FGD accumulation. If 
accurate differentiation is possible, FDG-PET might deserve a place in the 
follow-up and early screening for CA in CP patients. To this end, we studied 
the diagnostic efficacy of FDG-PET using a large cohort of patients with 
exclusively CP or CP complicated by CA (CP + CA), and included scans 
from patients with CA as a positive control.   
 
 
Materials and Methods 
 
Patient population  
Between March 2000 and March 2004, 109 Dutch patients with pancreatic 
disease from two university hospitals underwent FDG-PET: 77 in the CP 
group without suspicion of carcinoma, 26 in the CA group and six in the CP 
+ CA group (Table 1). 
 
Table 1 Patient characteristics 
 
CP  CA   CP + CA 
 
Number     77              26  6 
Age      45.9   59.5   64.5 
 
Sex 
   Male     50  10  5 
   Female     27  16  1         
 
FDG-positive:    10  24  5 
   Glucose > 10 mmol/la     1  1  0   
 
FDG-negative:    67  2  1 
   Glucose > 10 mmol/la    3  0   1 
 
Death      0  21  5 
 
a
 Fasting glucose level in mmol/l (normal level < 5.5 mmol/l) 
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Chronic pancreatitis group 
The CP group consisted of 77 adult patients (50 males, 27 females) (Table 
1). Clinical diagnosis of CP was based on one or more of the following 
criteria: presence of a typical history (recurrent upper abdominal pain, 
increased after eating with a rise in serum amylase) and suggestive 
radiological findings, such as pancreatic calcifications, pseudocysts or 
pancreatic ductal irregularities and dilatations, revealed by endoscopic 
retrograde pancreaticography (ERCP) or magnetic resonance imaging of the 
pancreas (MRCP) or by histology. Fifteen patients (19%) had a family history 
of CP. Diagnosis of hereditary chronic pancreatitis (HCP) was made on the 
basis of the presence of recurrent acute pancreatitis and/or CP in the 
absence of precipitating factors in two first-degree relatives or three or more 
second-degree relatives in two or more generations. Thirty-six patients 
(47%) had alcohol induced CP (ACP). ACP was diagnosed in patients with 
CP and an alcohol consumption of 60 g (females) or 80 g (males) per day for 
more than two years (14). Seventeen patients (22%) were classified as 
having idiopathic chronic pancreatitis (ICP) because they lacked obvious 
precipitating factors.  
Nine patients (12%) had risk factors such as trauma, medication, infection or 
metabolic disorders. On clinical grounds, there was no suspicion of CA. The 
average follow-up time was 22,1 months (5,6-46), and 66 patients had a 
follow-up period longer than 12 months.   
 
Pancreatic cancer group 
The CA group consisted of 26 patients (10 males, 16 females) with 
established CA referred to participating Surgical Departments (Table 1). 
Pancreatic cancer was confirmed either by histology (19 patients) or by 
radiological and clinical follow-up (7 patients).  
 
CP complicated by CA group 
This group consisted of six patients (five males, one female), referred to our 
hospital for analysis of jaundice or an enlarged pancreatic head (Table 1). 
They all had a well-established history of CP. Pancreatic cancer was 
confirmed either by histology (three patients) or by radiological and clinical 
follow-up (three patients).  
 
Exclusion criteria 
Patients were excluded if radiological and/or laboratory data and/or the 
presence of relevant clinical symptoms suggested a flair-up of pancreatic 
inflammation, because inflammation can lead to false-positive PET.  Patients 
with diabetes mellitus were excluded if the fasting glucose concentration 
exceeded 15 mmol/L, since high serum glucose levels are responsible for 
false-negative PET.  
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FDG-PET imaging 
A dedicated PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA) 
was used for data acquisition. Prior to FDG-injection, patients had been 
fasting for at least 6 h. Intake of sugar-free liquids was permitted. 
Immediately prior to the procedure, the patients were hydrated with 500 ml 
of water. One hour after intravenous injection of 200-220 MBq FDG 
(Mallinckrodt Medical, Petten, The Netherlands) and 12 mg furosemide, 
emission and transmission images of the area between the proximal femora 
and the base of the skull were acquired (10 min per bed position). The 
images were corrected for attenuation and reconstructed using the ordered 
subsets-expectation maximisation (OSEM) algorithm. The reconstructed 
images were displayed in coronal, transverse and sagittal planes. 
 
Interpretation    
For this study, FDG PET scans were analysed visually by one of the 
physicians from the Department of Nuclear Medicine and then reviewed by 
one of us (W.J.G.O) who was unaware of the original interpretation of the 
FDG-PET scan, the results of other diagnostic tests or the final diagnosis. 
Results were judged to be abnormal if focal accumulation of the tracer was 
detected in the area of the pancreas.  
Faint and/or diffuse FDG uptake in the pancreatic region (i.e. uptake slightly 
higher than uptake in the surrounding background, but clearly lower than 
liver uptake) was not considered suspicious for pancreatic cancer. 
Disagreements were resolved by consensus. 
 
Statistical analysis 
For the analysis of the categorical differences, we compared the groups 
using the Fisher's exact test. A two-sided P value of less than 0.05 was 
accepted as significant, and odds ratios and 95% confidence intervals are 
reported.  
 
 
Results 
 
The results are summarised in Tables 1 and 2. 
 
Table 2 FDG-PET results in the different groups 
 
CP  CA   CP + CA 
 
PET true positive    0            24       5 
PET false positive    10  0   0 
PET true negative             67  0  0 
PET false negative   0  2  1 
 
 Sensitivity 91% (29/32), specificity 87% (67/77), positive predictive value  
 74% (29/39), negative predictive value 96% (67/70). 
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CP group  
PET-positive cohort (n = 10): 
FDG-PET imaging demonstrated a focal hotspot in the area of the pancreas 
in ten CP patients. In three patients, including a patient with hereditary CP, 
there was only mild FDG uptake, and two of these three patients underwent 
rescanning that subsequently revealed normal distribution of the FDG tracer. 
Rescanning took place firstly because the FDG accumulation was merely 
mild and secondly because we were not able to explain the positive FDG-
PET. In seven other patients we detected high focal FDG uptake in the 
pancreas region. A single patient had an infected pseudocyst and FDG 
accumulation was visible in the tissue lining the cyst. The positive PET scan 
was followed in two patients by a Whipple resection because of CP-related 
pain, and histology of the pancreas demonstrated an infiltrate of 
mononuclear leucocytes consistent with acute inflammation (Figure 1). 
Another patient had a biliary endoprosthesis because of obstruction of the 
common bile duct precipitated by the enlarged pancreas head. One patient 
showed a normal distribution of FDG on the first scan, while  second and 
third FDG-PET scans demonstrated a focal hotspot. CT revealed a mass in 
the head of the pancreas, but the patient refused surgery. The remaining two 
patients had CP without additional lesions or complications. One of these 
two patients had low suspicion of CA and the other was simultaneously 
diagnosed with a hypopharyngeal carcinoma. None of the three CP patients 
with a positive scan in the absence of an apparent reason for the FDG 
uptake died during follow-up periods of 14, 21 and 28-months, respectively, 
or showed progression of disease. 
 
 
 
 
 
 
Figure 1 Coronal section of FDG-PET in a CP patient with inflammation; focal 
increased accumulation of FDG is visible in the area of the pancreas.  
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PET-negative cohort (n = 67): 
In 67 of the CP patients there was no focally increased uptake of FDG in the 
pancreas region. This yields a specificity of 87% for FDG-PET, with a 
negative predictive value of 96%. During the follow-up period none of the 
patients developed symptoms suggestive of CA, and all were alive at the 
end of the study.  
 
CA group 
PET-positive cohort (n = 24): 
Twenty-four CA patients had a positive FDG-PET scan with high focal 
uptake in the region of the pancreas. This results in a sensitivity of 91% and 
a positive predictive value of 74% for the detection of CA by FDG-PET. 
 
PET-negative cohort (n = 2): 
The first patient, a 50-year-old woman, presented with jaundice and weight 
loss. CT revealed an enlarged pancreatic head, enlarged lymph nodes and 
dilated bile ducts. FDG-PET demonstrated only minor upper abdominal 
uptake. A Whipple resection was performed, and histology showed a 
moderately differentiated carcinoma of the pancreatic head, with a diameter 
of 2,5 cm. The second patient, a 64-year-old male, came to our outpatient 
clinic with jaundice and colic pain in the right upper abdomen. CT was 
consistent with dilatation of the pancreatic and bile ducts. Endoscopic 
retrograde cholangiopancreaticography (ERCP) revealed a stenosis of the 
distal common bile duct (CBD) with dilatation of the proximal CBD and the 
pancreatic duct. A brush of the stenosis was done, and cytology 
demonstrated cells highly suspicious for adenocarcinoma. No focal uptake 
was seen on FDG-PET. A Whipple resection was done, and histology was 
compatible with focal (2.5-cm) pancreatic adenocarcinoma. Both patients 
were alive at the end of the study, with a follow-up period of 15 and 7 
months, respectively. 
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Patients with CP complicated by CA  
PET-positive cohort (n = 5): 
This group consisted of five patients (four males, one female). CT was 
compatible with a pancreatic mass in all patients while two patients 
additionally had dilated bile ducts. FDG-PET demonstrated focal 
accumulation of FDG in the pancreas (figure 2). One patient underwent a 
second FDG-PET study with an essentially similar result, although this latter 
scan revealed a larger area of FDG accumulation. None of the carcinomas 
seemed respectable owing to the very large size of the tumour mass, liver 
metastases or invasion of surrounding (vascular) structures. Two patients 
were treated with biliary bypass surgery, while another received a 
gastroenterostomy after intraoperative confirmation of malignancy. Two 
patients were treated with supportive care. All patients died during follow-up. 
 
 
 
 
 
Figure 2 Coronal section of FDG-PET in a patient with CA superimposed on CP 
(histology proven); focal increased accumulation of FDG is evident in the area of the 
pancreas. 
 
 
 
PET-negative cohort (n = 1): 
FDG-PET of a single CP patient demonstrated only weak FDG uptake in the 
liver region. CT showed enlargement of the pancreatic head. A Whipple 
resection was performed, and histological examination of the surgically 
removed pancreatic head revealed adenocarcinoma. This patient is alive at 
a follow-up period of 2 months.  
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Discussion 
 
Our study aimed to establish the value of FDG-PET in detecting CA in CP 
patients, on the grounds that the diagnostic ability of FDG-PET to detect CA 
has been recognised in a large sample of studies examining more than 
1.000 patients. The sensitivity of FDG-PET for CA diagnosis in patients 
presenting with a pancreatic mass varies between 68% and 100% and the 
specificity range from 65% and 100% (15-26). Our study confirms these 
data, as we found a sensitivity of 91% and a specificity of 87% for the 
detection of CA. We focussed our attention on patients with longstanding CP 
because this group, as a whole, has a 15- to 16-fold greater risk of CA 
compared with the general population (27). Patients with a subtype of CP, 
the hereditary form, are at a very high risk for CA, and a recent study 
estimated that 40% of these patients develop CA by the age of 70 years (6). 
Chronic inflammation of the pancreas can give rise to the same gross 
anatomical abnormalities as are seen in CA, such as pancreatic ductal 
irregularities and dilatations or enlargement of the pancreatic head. 
Particularly, in cases of pancreatic head enlargement, discrimination 
between CA and CP by CT, MRCP or ERCP is very difficult. Even 
endoluminal ultrasound, used as the first surveillance tool in familial CA (28), 
is unable to differentiate between CP and CA (29). Moreover, CA can mimic 
the clinical symptoms of an exacerbation of CP. These data reflect the 
intrinsic difficulties that face the clinician in the follow-up of CP patients as 
such patients run a high risk for CA that is less likely to be detected with 
conventional imaging techniques at an early, curable stage. The literature 
mostly deals with patients first presenting with a pancreatic mass in which  
differentiation between CP and CA is needed. To our knowledge, no studies 
have been published on the additional value of FDG-PET in patients with 
known CP.  
We evaluated the value of FDG-PET in CP and detected FDG accumulation 
in 15 patients (10 with CP and 5 with CP complicated by CA). We then 
focussed on the most important question: do all these patients have CA 
superimposed on CP or are there other reasons for the positive scan? Our 
results suggest that minor FDG uptake in CP patients is, in most cases, not 
associated with serious pathology and that close follow-up with rescanning 
suffices. High pancreatic FDG uptake in a CP patient should be considered 
a reason for intense scrutiny. Clinical evaluation should assess whether 
there is an obvious non-malignant cause for FDG accumulation. Our data 
corroborate the finding that infection of a pseudocyst or local inflammation 
caused by placement of a biliary stent can cause false-positive FDG uptake 
(30). We also detected that exacerbation of CP-related chronic abdominal 
pain precipitates high focal pancreatic FDG uptake, indicating an 
inflammatory component of this phenotype. In addition, our results show that 
in cases of CP complicated by CA, FDG-PET reveals clear FDG uptake. In 
total, five of six such patients demonstrated a hotspot on FDG-PET and all 5 
died within a year after diagnosis. Whether or not FDG-PET can detect early 
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carcinomas in CP patients was difficult to address in our patient series, as 
the patients with CP complicated by CA came to our attention at a relatively 
late stage of the disease. The fact that FDG-PET is indeed able to detect CA 
in the context of longstanding CP, and that the large majority of CP patients 
(87%) had negative scans despite years of disease, might indicate that this 
modality can be used as a tool to screen for early carcinoma in CP. A future 
diagnostic step might include image fusion of CT or MRI with FDG-PET. The 
overlay superimposes the biochemical detection data over the anatomical 
information as generated by CT or MRI. This will permit more accurate 
localisation of the region of FDG uptake. This concept has yet to be explored 
in the detection of CA but the first reports illustrate its feasibility(31;32). Our 
series also included 3 CP patients with a positive scan in the absence of an 
apparent reason for the FDG uptake. These scans were probably false 
positive, because there were no signs of infection and follow-up was long 
enough to exclude CA (14, 21, 28 months). We adopted a policy of close 
follow-up in these patients and weighed the clinical evidence. The findings 
imply that a positive PET scan in CP should lead to further examinations 
even if this necessitates surgery to rule out CA. In cases of inconclusive 
evidence and a low clinical suspicion of CA, close clinical follow-up is 
advised.  
Another potential confounder in interpreting FDG-PET is a high fasting 
glucose level, owing to competitive FDG displacement by the high glucose 
level. In patients with elevated fasting serum glucose (> 130 mg/dl, 6,4 
mmol/L), the sensitivity of FDG-PET was found to decline (33). Both CP and 
CA often present with a mild or severe endocrine pancreatic insufficiency, 
and in our study 30 patients had a fasting glucose > 6,4 mmol/L. However, 
high fasting glucose levels did not markedly influence the FDG-PET results 
in our study. Neither of the two PET-negative CA patients had a high blood 
glucose level. It is possible that a high glucose level played a role in the 
minor uptake in the liver area in the patient with CP and CA. On the other 
hand, our series contains seven patients in either the CA or CP group who 
had an obvious raised glucose level (glucose > 8 mmol/L) and who 
demonstrated a clear hotspot in the region of the pancreas.  
 
 
Conclusion 
 
This study demonstrates that, in the majority of CP patients, FDG-PET will 
yield negative results, but that in CP complicated by CA, PET scans are 
usually positive. This suggests that FDG-PET could be used as a screening 
tool in CP patients with a high risk for CA, such as those with hereditary CP. 
We also confirm that FDG-PET is able to differentiate between CP and CA, 
with a sensitivity of 91% and a specificity of 87%. 
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Abstract 
 
Purpose:  Familial adenomatous polyposis (FAP) is characterised by colonic 
and duodenal adenomatous polyps that carry a risk of malignant 
transformation. Malignant degeneration of duodenal adenomas is difficult to 
detect. We speculated that 2-(18F)-fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET) might be able to detect early duodenal 
cancer in FAP. Accordingly, we investigated the role of FDG-PET in the 
management of FAP patients. 
Methods:  FDG-PET was performed in 24 FAP patients. Eight had advanced 
duodenal adenomas (Spigelman IV), including two patients with duodenal 
cancer. Scans were defined positive on the basis of focal FDG 
accumulation.  
Results:  Pathological FDG accumulation was absent in 19 of 24 patients. All 
six patients with Spigelman IV duodenal adenomas (without cancer) were 
negative; two of these underwent a duodenectomy and pathological 
examination did not reveal duodenal cancer. In five patients, FDG-PET 
revealed significant uptake, in the duodenum (2), lower abdomen (1), lung 
(1) and multiple sites in the abdomen (1). These hot spots correlated with 
duodenal cancer (2), abdominal metastasis (1), and sclerosing 
haemangioma of the lung (1). We failed to make a histopathological 
diagnosis in the single patient with multiple intra-abdominal sites of FDG 
uptake. None of the patients from the FDG-PET-negative group developed 
cancer during follow-up (mean 2.8 years). 
Conclusion: FDG-PET detected all the cancers present, and none of the 
patients with negative FDG-PET developed cancer. This suggests that 
positive FDG-PET in FAP patients should lead to further examinations to 
rule out cancer. In patients with a negative FDG-PET a more conservative 
approach seems justified.  
 
 
Introduction 
 
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited 
disorder that is caused by germline mutations in the adenomatous polyposis 
coli (APC) tumour suppressor gene and is characterised by the development 
of multiple colonic adenomatous polyps. FAP occurs in a frequency of 
approximately in 1 of 10,000 live births among the general population (1). 
Apart from colonic adenomas, 58-90% of FAP patients develop duodenal 
adenomas and this is associated with an approximately 300 times higher risk 
for duodenal cancer (2-6) compared with the general population. Once 
duodenal carcinoma is diagnosed, the prognosis is dismal. The clinical 
challenge is to identify high-risk patients with duodenal adenomas and to 
intervene before progression to cancer. At present, FAP patients are 
screened by side-viewing upper gastrointestinal endoscopy with biopsies to 
assess the severity of the duodenal adenomas,  
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with special emphasis on the peri-ampullary region. Duodenal adenomas are 
classified according to the modified Spigelman classification (7). This 
classification is helpful in estimating the cancer risk, which is 36% after 10 
years in Spigelman IV (Table 1) (7;8).  
 
 
Table 1 Modified Spigelman’s score and classification. 
 
      Score 
 
Factor     1 point  2 points  3 points 
 
Number of polyps   1-4  5-20  > 20 
Polyp size, mm   1-4  5-10  > 10 
Histology   Tubular  Tubulovillous Villous 
Dysplasia   Low-grade -  High-grade 
 
 
The side-viewing upper endoscopy results are classified according to number of 
polyps, size of the polyps, histology and dysplasia grade. For all these parameters 
the patient receive points (1-3) and the sum represents in the Spigelman score. 
Classification: no polyp: stage 0; 1-4 points: stage I; 5-6 points: stage II; 7-8 points: 
stage III; 9-12 points: stage IV 
 
 
However, endoscopy has limitations; for example, the risk of biopsy 
sampling error is high. In some series, the resection specimens demon-
strated invasive carcinoma in 28-49% of patients with negative pre-operative 
biopsies (3;6;9). Other diagnostic modalities, such as endoscopic ultrasound 
and magnetic resonance imaging seem promising, but more studies are 
warranted before their routine implementation in clinical practice (10-12). 
The current standard approach in patients with advanced duodenal 
adenomas (Spigelman IV) is a preventive, pancreas-preserving duodenal 
resection or a classic pancreaticoduodenectomy. These operations carry a 
significant morbidity and mortality and adenomas will probably reappear in 
the neo-duodenum (13-15). This emphasises that stringent patient selection 
and optimal timing of surgery is crucial in FAP-associated duodenal 
adenomas. 
Recently, whole-body 2-(18F)-fluoro-2-deoxy-D-glucose positron emission 
tomography (FDG-PET) has been established as an important tool in clinical 
oncology. It is clinically used to detect a wide variety of tumours including 
lymphoma, melanoma, lung cancer, pancreatic and colon cancer as well as 
benign disorders such as vasculitis (16;17).  
We assessed he diagnostic yield of FDG-PET in FAP patients, especially 
those with duodenal adenomas. Our hypothesis was that FDG-PET is able 
to detect malignant degeneration of duodenal adenomas. 
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Materials and Methods 
 
Patient population  
Between June 2000 and October 2004, 24 adult Dutch patients with FAP 
who visited the outpatient clinic of the Department of Gastroenterology and 
Hepatology at the Radboud University Nijmegen Medical Centre were in-
cluded in the study. The group consisted of 24 patients (14 males, 10 
females) (Table 2) with a mean age of 47.3 (SD 12.0).  
 
 
Table 2 Patient characteristics. 
 
Patient characteristics (n=24) 
 
Sex; (M:F)    14:10 
Mean age    47.3 (SD12.0) 
Spigelman classification      0: 2 
     I: 3 
     II: 9 
     III: 2 
     IV: 8 
Status of the colon    Ileo-anal pouch: 3 
     Ileorectal anastomosis: 9 
                     Ileostomy: 9 
     Colon in situ: 2 
Mutation analysis    Positive: 7 
     Unknown/negative: 16 
Mean follow-up    2.78 years (0.02-4.41) 
Deceased patients   3 
 
 
 
FAP was diagnosed based upon the presence of more than 100 
adenomatous colorectal polyps and a positive family history, or by genetic 
testing on an APC mutation. Four (17%) patients underwent procto-
colectomy with ileal pouch anal anastomosis (IPAA), nine patients (38%) 
had a proctocolectomy with ileorectal anastomosis, another nine (38%) 
underwent subtotal colectomy with an end ileostomy. The remaining two 
(7%) patients still had their colon in situ. These colonic interventions were 
performed at least 2 years before FDG-PET. The mean follow-up time was 
33 months (1-53), and 18/24 patients had a follow-period after FDG-PET of 
longer than 12 months. 
 
FDG-PET imaging 
A dedicated PET-scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, 
USA) was used for data acquisition. Prior to FDG-injection, patients fasted 
for at least 6 h. Intake of sugar-free liquids was permitted.  
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Immediately prior to the procedure, the patients were hydrated with 500 ml 
of water. One hour after intravenous injection of 200-220 MBq FDG 
(Mallinckrodt Medical, Petten, The Netherlands) and 12 mg furosemide, 
emission and transmission images of the area between the proximal femora 
and the base of the skull were acquired (10 minutes per bed position). The 
images were corrected for attenuation and reconstructed using the ordered 
subsets expectation maximisation (OSEM) algorithm. The reconstructed 
images were displayed in coronal, transverse and sagittal planes. 
All FDG-PET scans were performed in a period around the upper 
gastrointestinal endoscopy and before possible surgery for duodenal 
adenomas/carcinoma.   
 
Interpretation  
For this study, FDG PET scans were analysed visually by one of the 
physicians from the Department of Nuclear Medicine and then reviewed by 
one of us (W.J.G.O.) who was unaware of the results of the original 
interpretation of the FDG-PET, the results of other diagnostic tests or the 
final diagnosis. Results were judged to be abnormal if focal accumulation of 
the tracer was detected. Disagreements were resolved by consensus. 
 
Endoscopy 
A side-viewing upper gastrointestinal endoscopy procedure was performed 
in all patients and colonic endoscopy was performed in patients with 
ileorectal anastomosis or ileo-anal pouch. The procedures were performed 
by a gastroenterology resident directly supervised by an experienced 
gastroenterologist (F.M.N.) or by F.M.N. himself. The endoscopist was 
unaware of the FDG-PET results. Indigo carmine chromo-endoscopy was 
performed in almost all procedures. All polypoid lesions were biopsied. 
Larger adenomas were removed whenever possible or biopsied. All tissue 
specimens were immediately fixed in 10% buffered formalin solution before 
examination using haematoxylin and eosin staining. Each polyp was 
classified by an experienced pathologist (J.v.K.) as adenoma or polyp of 
another type. Dysplasia was defined according to the Vienna criteria as 
either low-grade dysplasia or high-grade dysplasia (18). The endoscopy was 
considered negative in the presence of normal mucosal findings (after indigo 
carmine) and normal histology or if polyps were hyperplastic on histo-
pathological examination. Endoscopy was considered positive when 
histopathology confirmed the presence of either adenomas or carcinomas. 
The endoscopic findings were reported in terms of the site, quantity and size 
of adenomas.  
The adenomas of the duodenum were classified according to the modified 
Spigelman classification (Table 1) (7).  
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Statistical Analysis 
For analysis of the categorical differences, we compared the groups using 
the Fisher's exact test. A two-sided P value of less than 0.05 was accepted 
as significant and odds ratios and 95% confidence intervals are reported.  
 
 
Results 
 
PET-positive cohort (n = 5) 
FDG-PET demonstrated focal accumulation in five patients; in the other 19 
patients all scans were negative. Table 3 shows the characteristics and final 
diagnoses of the FDG-PET positive group. 
 
 
Table 3 Characteristics of FDG-PET positive patients 
 
Patient no.  Sex Age (yrs) PET-positive Final diagnosis  
 
1  F 50  Duodenum Duodenal cancer  
2  F 68  Duodenum Duodenal cancer 
3  M 35  Lower abdomen Proven metastasis 
4  F 52  Left lung  Sclerosing                
                                                                        Haemangioma  
5  M 38  Diffuse abdomen No explanation for   
                                                                          positive PET  
 
 
 
The first patient, a 50-year-old female with a medical history compatible with 
caecal, rectal and pouch carcinoma, all successfully treated by surgery, 
presented with iron-deficient anaemia. Upper endoscopy revealed an 
ulcerative mass close to the Vater’s papilla. Histological examination 
demonstrated adenomatous tissue with high-grade dysplasia. FDG-PET 
displayed a hot spot in the upper abdomen (Fig. 1). Because of the high 
suspicion of duodenal carcinoma a Whipple’s resection was carried out. The 
resection specimen showed invasive adenocarcinoma, with local lymph 
node metastasis. After 1 year, lung metastases were diagnosed and she 
was treated with chemotherapy. She died at age 51, probably due to 
massive lung embolism. 
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Figure 1 Coronal sections of FDG-PET in a FAP patient with duodenal cancer near 
Vater’s papilla. Focally increased accumulation of FDG is present in the upper 
abdomen. 
 
 
The second patient was a 68-year-old female, known to have multiple 
duodenal adenomas since 1993. FDG-PET in 2000 showed minor focal 
uptake in the upper abdomen. Upper endoscopy again demonstrated large 
duodenal adenomas with only high-grade dysplasia. Endoscopic ultrasound 
was performed and demonstrated no definitive proof of malignancy. She was 
referred for duodenal resection because she was thought to be at high risk 
for duodenal carcinoma. After extensive deliberations a conservative policy 
was adopted because of the lack of histopathological proof of malignancy, 
her general condition and her refusal to undergo major surgery. Biopsies 
taken during an upper endoscopy in 2002 (2 years after positive FDG-PET) 
showed adenocarcinoma. She developed anaemia due to tumour-related 
chronic blood loss. Radiotherapy was started to reduce blood loss and a 
duodenal endoprosthesis was placed. She died 6 months later, 3 years after 
the first positive FDG-PET. 
 
The third patient, a 35-year-old male, had a history of a proctocolectomy with 
IPAA. In 1999 the pouch was excided because of a pouch carcinoma. FDG-
PET performed in 2002 showed two hotspots in the lower abdomen. 
Computed tomography (CT) demonstrated a mass in the lower abdomen. 
Partial resection followed and histopathological findings were compatible 
with a metastasis of the known pouch carcinoma. Chemotherapy followed 
and he died of progressive disease a year later. 
 
The fourth patient, a 52-year-old female, had a history of proctocolectomy 
with an ileostomy. FDG-PET demonstrated a focal hotspot in the left lung. A 
CT scan demonstrated a tumour, with suspicion on a lung carcinoma. 
Ultimately, resection of the tumour was performed, and histopathological 
examination showed a sclerosing haemangioma. There was also a polyp on 
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the border of the ileostomy which had high-grade dyplastic characteristics. 
This lesion appeared to be FDG-PET negative. 
 
In the last patient, a 38-year-old male, who also had idiopathic chronic 
pancreatitis, two FDG-PET scans revealed multiple hotspots in the upper 
and lower abdomen. In the first scan, only minor uptake was seen; however 
in the second scan, the accumulation was more intense. Abdominal CT 
showed calcifications in the head of the pancreas, compatible with chronic 
pancreatitis, but no tumour. Upper endoscopy showed a Spigelman II and 
lower endoscopy demonstrated multiple small rectal adenomas, with only 
low-grade dysplasia. Because of the lack of symptoms and the absence of 
an anatomic abnormality on CT, we elected to adopt a wait-and-see policy. 
After a follow-up of almost 4 years there has been no progression of 
disease. 
 
PET-negative cohort (n = 19) 
In 19 patients there was no focally increased uptake of the tracer on FDG-
PET. In all but two patients, upper endoscopy revealed duodenal adenomas. 
Six patients had Spigelman classification IV and two of these six patients 
underwent subsequent pylorus-preserving duodenal resection. Histo-
pathological examination of the resection specimen in both patients 
demonstrated high-grade dysplasia. In one patient the adenoma with high-
grade dysplasia was resected by duodenotomy. In one patient, endoscopic 
therapy with plasma coagulation of the largest adenoma was performed. The 
remaining two patients are intensively followed by endoscopy.  
Some 10/19 patients had multiple small (< 5 mm) adenomas in the pouch or 
rectum. The histopathological stage varied between low- and high-grade 
dysplasia. FDG-PET detected none of these adenomas.  
 
 
Discussion 
 
As far as we know, this is the first study of the diagnostic yield of FDG-PET 
in FAP patients. We included a limited number of 24 FAP patients. Most of 
these patients underwent early colectomy to prevent primary colonic cancer. 
However, they are still at increased risk of developing malignancies in other 
organs such as the duodenum and the pouch. All but two of the patients had 
duodenal adenomas, and three patients had an IPAA on the moment of 
FDG-PET. In five patients, PET revealed FDG hot spots. FDG-PET detected 
all carcinomas within our series. Two patients had duodenal carcinoma and 
one patient, metastases of a pouch carcinoma. None of the FDG-PET-
negative patients developed cancer during a long follow-up. In one patient 
the increased accumulation of FDG appeared to be a sclerosing 
haemangioma, and in the last patient no lesion was found even after 
thorough investigations.  
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This results in a sensitivity of 100% (3/3) and specificity of 90% (19/21) for 
detection of cancer at any site in FAP patients. Our data suggest that FDG-
PET might be added to the diagnostic work-up of these patients with an 
increased malignancy risk. 
As indicated above, in one patient we detected a 2-cm sclerosing 
haemangioma of the left lung. Recently, Hosaka et al. described a case of a 
patient with attenuated FAP in whom FDG-PET led to discovery of a 
sclerosing haemangioma in the right lung (19). They suggest an association 
between the two diseases as both the sclerosing haemangioma and the 
adenomas displayed aberrant nuclear and cytoplasmic expression of β-
catenin. Expression of aberrant nuclear and cytoplasmic β-catenin is also 
seen in FAP associated colon and thyroid cancer. This phenomenon is 
probably due to dysregulated Wnt signalling; the APC gene is part of the 
Wnt signalling (20;21). In 2001, Hara et al. demonstrated for the first time 
detection of a sclerosing haemangioma by FDG-PET (22). As in our case, 
they found only minor lesional FDG uptake. Excision of a sclerosing 
haemangioma is probably the best therapeutical option, given the tendency 
of local invasion and lymph node metastasis (23;24). False-positive results 
are a disturbing aspect of any diagnostic tool, and FDG-PET is no exception; 
in our series, only one patient had a false-positive result. This patient had 
been diagnosed with FAP and chronic pancreatic. At the time of FDG-PET 
there were no radiological and/or laboratory data and/or clinical symptoms to 
suggest a flair-up of pancreatitic inflammation, which can lead to false 
positive PET. Four years after the initial positive FDG-PET, there are no 
abnormalities on CT and the patient remains free of symptoms. We 
considered the hotspots as non-specific uptake in the abdomen. 
FDG-PET changed the therapeutic management in two patients. In one 
patient, FDG-PET detected, previously unknown metastases of a pouch 
carcinoma and this patient was treated with surgery followed by 
chemotherapy. The other patient was treated surgically for the sclerosing 
haemangioma detected by FDG-PET.  
We were able to follow the natural history of duodenal adenomas that 
accumulate FDG in a single patient. This patient adamantly refused surgery 
and at that time the implications of a positive FDG-PET with negative 
histology were unclear. This case took a dramatic course, and the patient 
subsequently developed overt duodenal cancer.  
It is worth noting that, in this study, none of the FAP associated colonic 
adenomas were detected by FDG-PET, even though some adenomas 
showed high-grade dysplasia on histopathological examination. This is 
interesting because recently published studies demonstrated that FDG-PET 
detects sporadic colonic adenomas (25;26). In a study among 68 patients 
with colonic adenomas, we found that FDG-PET detected 81% of the 
adenomas with high-grade dysplasia or carcinoma and 80% of the 
adenomas > 15 mm. The grade of dysplasia was the most important 
discriminative factor that predicts detection by FDG-PET (27).  
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From the current study we hypothesise that colonic as well as duodenal FAP 
adenomas remain negative on FDG-PET, independent of the dysplasia 
grade or size. FDG accumulation appears only in carcinomas. While the 
mechanism for this difference remains unclear, FDG-PET appears to be a 
clinically useful tool for differentiation between adenoma and carcinoma in 
FAP.  
 
 
Conclusion 
 
FDG-PET detected all the carcinomas in this FAP patient group with 
duodenal adenomas, while none of the FDG-PET-negative patients 
developed (duodenal) cancer. This suggest that positive FDG-PET in FAP 
patients affects clinical management, leading to further examinations even if 
this necessitates surgery to rule out primary cancer or unsuspected 
metastases. In patients with negative FDG-PET, a more conservative ap-
proach seems justified.  
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Abstract 
 
Background: Azoxymethane (AOM) is a potent carcinogen that induces 
colorectal cancer and adenomas in rats. [18F]FDG-PET is a molecular 
imaging technique that is based on the elevated uptake and retention of 
radiolabeled glucose. At present, it is unknown at which stage FDG 
accumulation occurs during the adenoma carcinoma sequence. To address 
this issue, we studied the FDG uptake in AOM-induced rat colorectal 
adenocarcinoma (CRC) and correlated this with histopathological findings.  
Methods: Seventy Fischer 344 rats were injected with AOM. Terminal 
autopsy took place 20-38 weeks after the first AOM injection. After [18F]FDG 
PET scanning, the rats were sacrificed, tissue [18F]FDG uptake was 
measured, followed by histopathological examination.  
Results: Macroscopic examination revealed 21 tumours (7 located in the 
small bowel and 14 in the colon) in 19 rats. On histological examination, we 
found 10 colonic adenocarcinomas (the first being observed at Week 22) 
and 7 adenocarcinoma in the small bowel. In total, seven colon adenomas 
were found in five rats, six of which expressed high-grade dysplasia. The 
[18F]FDG accumulation in small intestine carcinomas was well beyond 
background accumulation (p<.0001). On PET scanning two rats showed 
focal accumulation of the abdominal area, corresponding to small intestine 
carcinomas. 
Conclusion: Adenocarcinomas had a significantly higher [18F]FDG uptake 
than background bowel uptake. [18F]FDG uptake was lower in adenomas 
than in carcinomas. These data suggest that the AOM model allows the 
evaluation of intervention strategies with [18F]FDG uptake as a valid outcome 
measure.  
 
 
Introduction 
 
Colorectal adenocarcinoma (CRC) is highly prevalent and a common cause 
of cancer-related deaths in the Western world (1;2). The high disease 
burden has led to experimental carcinogenesis models that allow the study 
of the biology of cancer and the evaluation of pharmacological interventions. 
Azoxymethane is a potent carcinogen that induces colorectal cancers in rats 
and mice. The spectrum of AOM-induced epithelial lesions resembles those 
of the various types of neoplastic lesions in human CRC. In addition, AOM-
induced CRC appears to follow the concept in which tumour initiation is 
followed by tumour promotion and progression in a sequential manner. 
Specifically, AOM induces the onset of aberrant crypt foci, as the precursor 
lesion, followed by the onset of adenocarcinoma most often of the distal 
colon, and finally metastasis to mesenteric lymph nodes and liver. The 
molecular pathogenesis is characterized by K-ras and/or beta catenin 
mutations.  
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Unique to the AOM rat model is the co-occurrence of both adenomas and 
adenocarcinomas, and it has been estimated that 70% of colon tumours are 
adenocarcinomas, while the remainder are adenomas. Histologically, 
adenomas of the colon are noninvasive with low- to high-grade dysplasia (3).   
[18F]FDG-PET is a molecular imaging technique that is based on the 
elevated uptake and retention of radiolabeled glucose in target tissues. The 
FDG uptake detected by scans allows for estimation of the cellular energy 
metabolism  and can be used to detect stage and assess treatment of many 
processes, most notably malignancies (4). FDG-PET has also been used for 
research purposes because it offers metabolic/functional images 
noninvasively, quantitatively, and repeatedly, not only  in humans but also in 
small animals. At present, it is unknown at which stage FDG accumulation 
occurs during the adenoma-carcinoma sequence of CRC. We reasoned that 
the CRC of the AOM rat model is associated with higher metabolic activity 
and hence increased FDG uptake. Furthermore, this model allows us to 
evaluate whether FDG already accumulates in adenomas. Ultimately, our 
goal is to develop an experimental model of metabolic imaging that 
visualizes the carcinogenesis of CRCs. An ideal model would allow 
noninvasive monitoring of the efficacy of cancer intervention/prevention 
strategies. To address this issue, we studied the FDG uptake in AOM-
induced rat CRC and correlated this with histopathological findings.  
 
 
Materials and Methods 
 
Experimental model 
We used the AOM rat model (5) because of the apparent similarity of the 
induced tumours to those occurring in humans (6). These animals develop 
colonic adenomas and colon carcinomas within 5 months after AOM 
treatment (7) . We obtained 70 male weanling Fischer 344 rats from Charles 
River (Sulzfeld, Germany). Animals were kept on softwood bedding in 
macrolon cages, two or three per cage, under standard laboratory 
conditions. Rats were fed the Institute’s stock diet for rats. Azoxymethane 
(NCI Chemical Carcinogen Reference Standard Repository, Midwest 
Research Institute, Kansas City, MO) was diluted in 0.9% NaCl to a final 
concentration of 15 mg/ml. Standard safety precautions were taken during 
handling of the AOM and the animal treated with the AOM. The rats were 
subcutaneously injected weekly for 3 consecutive weeks with 15 mg AOM/kg 
body weight from the age of 9 weeks onwards. A control group (n=7) was 
injected with saline. Terminal autopsy of the rats took place in groups of 
seven animals, at a 2-week interval starting at 20 weeks after the first AOM 
treatment. The experiment was reviewed and approved by the local animal 
welfare committee according to the Dutch governmental guidelines. Animals 
suffering from advanced disease prior to their planned dissection were 
euthanized according to these same guidelines. 
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 [18F]FDG accumulation 
[18F]FDG was obtained from Tyco Mallinckrodt Medical (Petten, The 
Netherlands). Specific activity was higher than 1 GBq/µmol, and 
radiochemical purity was always higher than 97% (end of synthesis). After a 
6-hour fast, rats were injected intravenously with 3.7 MBq [18F]FDG via the 
lateral tail vein. Intravenous  injections into the tail veins were performed by 
a skilled biotechnician. No residual activity could be measured in the tails of 
the rats, indicating no extravasations upon the tail vein injections. One hour 
after [18F]FDG injection, the rats were anaesthetized with a mixture of 
isoflurane/O2/N2O and a PET scan was performed on a ECAT EXACT 
scanner (Siemens/CTI, Knoxville, TN, USA). After the PET scan, the rats 
were killed by CO2 suffocation and a blood sample was obtained by cardiac 
puncture; then the animals were examined for gross pathological changes. 
Parts of the lung, liver, kidney, muscle, spleen, small intestine and three 
parts of the colon (distal, proximal and cecum) were excised and weighed, 
and [18F]FDG activity was measured in a shielded well-type gamma counter 
(Wizard, Pharmacia-LKB, Uppsala, Sweden). The contents of the small 
intestine and colon were removed before measurements. [18F]FDG uptake 
was expressed as percentage of the injected dose per gram tissue (%ID/g). 
The entire large bowel was excised from each animal, fixed in 4% buffered 
formalin and their [18F]FDG accumulation was measured, as described 
above.  
 
Histopathology of the large bowel 
The large bowel specimen of at least two rats per group (those with the 
highest and lowest [18F]FDG accumulation) and those with macroscopic 
signs of tumour was processed for microscopy by conventional methods, 
stained with haematoxylin and eosin (H&E), and examined by light 
microscopy. All tumours were classified as adenomas or carcinomas. 
Adenomas were subclassified as tubular, tubulovillous and villous. Dysplasia 
was defined according to the Vienna criteria as either low- or high-grade 
dysplasia (8). Small bowel tumours were also classified as adenomas or 
carcinomas.  
 
Statistical analysis  
The paired nonparametric Wilcoxon signed rank test was used for statistical 
comparison of values obtained in rats with an adenoma or carcinoma vs. 
rats without an adenoma or carcinoma. The unpaired nonparametric Mann-
Whitney U test was used where appropriate. Probability ( P ) values were 
calculated on the basis of two-tailed tests. A correlation coefficient was 
calculated with the Pearson’s correlation test. A P value of < .05 was 
considered to be the lowest level of significancy. Data are given in mean ± 
S.D. 
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Results 
 
Macroscopic examination 
Macroscopic examination of small and large bowels revealed 21 tumours in 
19 rats, which started to appear 22 weeks after the first AOM injection. 
Macroscopic inspection of the intestines demonstrated small bowel tumours 
in 7 animals, all located in the proximal part of the small bowel directly distal 
from the stomach. Fourteen tumours were located in the large bowel (n=4 
distal part, n= 9 mid large bowel, n=1 cecum). Two animals had more than 
one gastrointestinal tumour. One rat had tumours in both small and large 
bowel, while the colon of another animal contained two tumours, one in the 
colon transversum and one in the distal part. The remaining animals were 
free of macroscopic signs of gastrointestinal tumour growth, but a single 
animal had metastatic tumour growth spread to the abdominal cavity. No 
other gross macroscopic changes were observed. 
 
Histological examination 
The first group of rats, dissected 20 weeks after start of AOM treatment were 
free of histological abnormalities.  At week 22, we observed the first colonic 
adenocarcinoma, and  this animal also had an adenoma in the same part of 
the large bowel. The first adenocarcinoma in the small bowel was observed 
24 weeks after the first AOM injection. In total, seven colon adenomas were 
found in five rats. Only two rats showed an adenoma without a carcinoma in 
the same part of the colon. All other five adenomas appeared in a part of the 
colon that also contained a carcinoma. Nearly all adenomas expressed high-
grade dysplasia (6/7); only one showed low-grade dysplasia.  
We found 10 colonic adenocarcinomas and 7 small intestinal carcinomas. 
None of the rat intestines had signs of inflammation. Desmoplasia was only 
seen in rat intestines containing cancer. These findings are in good 
correlation with previous findings (3). 
 
[18F]FDG accumulation 
Fig. 1 depicts mean [18F]FDG accumulation in non-affected small intestine, 
colon and in adenomas and carcinomas in both tissues. The [18F]FDG 
accumulation in the carcinomas in the small intestine greatly contrasted to 
the background (P<.0001). Target-to-background ratio was 2.5. Difference in 
uptake in carcinoma in the colon as compared to normal colon was less 
pronounced, but still significant (P= .006), with a target-to-background ratio 
of 1.6. In two rats with adenomas, but without carcinomas, [18F]FDG uptake 
in adenomas was not higher than [18F]FDG uptake in non-affected colon 
(0.56 ± 0.06 vs. 0.69 ± 0.21 %ID/g, respectively, P= .1). [18F]FDG 
accumulation in tumours was higher than that in all other organs (Fig. 2). 
[18F]FDG uptake in the organs not affected by AOM did not change in 
relation to AOM treatment, i.e. during the time course of the experiment 
(data not shown).  
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[18F]FDG uptake in non-affected colon was similar to that of [18F]FDG uptake 
in colon in a group of control rats (p= .95), indicating that the AOM did not 
affect [18F]FDG accumulation in normal tissue.  
Fig. 3 shows an [18F]FDG-PET scan of four rats. In two rats, focal 
accumulation is noted in the abdominal area. After dissection, these proved 
to be carcinomas of the small intestine.  
 
 
 
Figure 1 Box and Whisker plot of [18F]FDG accumulation in the small intestine (A) 
and colon (B) (“background”) compared to [18F]FDG uptake in carcinomas and 
adenomas found in the corresponding tissues. Uptake is expressed as %ID/g. 
Significant differences between carcinomas and corresponding background tissues 
are depicted. * P <.0001; ** P =.006. 
 
 
 
Figure 2 Biodistribution of [18F]FDG in tumor-bearing rats. Uptake is expressed as 
%ID/g: error bars indicate standard deviation. 
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Figure 3 Coronal sections of [18F]FDG-PET in an AOM-treated rat; focal increased 
accumulation of [18F]FDG in the area of the colon (arrows).  
 
 
Discussion 
 
In the present study, we investigated whether [18F]FDG accumulates 
preferentially in (pre)malignant lesions induced by AOM in an experimental 
rat model. Here we show that three subcutaneous injections of AOM induced 
both adenomas and adenocarcinomas in the colon as well as small intestine 
carcinomas in F344 rats. The first adenomas appeared 22 weeks after the 
start of AOM injections. There was no correlation between time after AOM 
treatment and the appearance of gastrointestinal adenomas and 
carcinomas. This study shows that  [18F]FDG uptake in the carcinomas is 
high and allows noninvasive detection of the tumours in both small intestine 
and colon. [18F]FDG uptake of colon sections that contained adenomas was 
not significantly higher compared to that of nonaffected colon tissue. The 
individual adenomas were relatively small (<2 mm) and escaped 
macroscopical detection. Instead, we counted radioactivity of complete 
intestinal and colonic segments. Therefore our study does not allow a 
comprehensive assessment of the ability of individual small adenomas to 
accumulate FDG. We know from clinical studies that [18F]FDG-PET has 
limited sensitivity for the detection of small premalignant colonic adenomas. 
Several studies concluded  that the detection of adenomas with [18F]FDG 
improved with the size of the adenomas (9;10). Yasuda et al. studied the 
detection of colonic adenomas in 110 patients and found that  FDG-PET was 
positive in only 14 (24%) of  59 adenomas (9). However, the positivity rate 
increased to 90% in the larger adenomas (>13 mm). Another study 
corroborated these findings and showed that the sensitivity of FDG-PET was 
21% in small adenomas (1 to 5 mm) but increased to 72% in larger 
adenomas  (> 11 mm) (10). These results confirm our present findings. 
Positron emission tomography scanning showed tumour-specific colonic 
[18F]FDG uptake of those animals that upon resection possessed relatively 
large carcinomas.  
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We detected only a few carcinomas by PET, and this can readily be 
explained by the spatial resolution of the clinical PET scanner used (5.0 mm) 
rather than a dedicated animal PET scanner which was unavailable to us. 
Whereas the clinical studies focused on the detection of the adenomas with 
PET, we performed ex vivo biodistribution studies in order to quantitatively 
measure FDG uptake. These results indicate  that apart from adenoma size, 
the absolute uptake of FDG in the adenoma is crucial. In our experimental 
model, uptake was lower in the macroscopically detected adenomas than in 
carcinomas. This is in line with other studies that show that dysplasia grade 
is a major independent factor that determines FDG uptake (10). In general, 
standard uptake values increase with grade of dysplasia and is highest in 
carcinomas. The majority of adenomas contained foci of high-grade 
dysplasia.   
From the present study, we may conclude that AOM treatment leads to 
colonic adenomas and adenocarcinomas. Adenocarcinomas had a 
significantly higher [18F]FDG uptake than background bowel uptake. 
[18F]FDG uptake is lower in adenomas than in carcinomas, which is due to a 
lower absolute tissue uptake. These data suggest that the AOM model is a 
valid CRC model that allows the evaluation of intervention strategies with  
[18F]FDG uptake as a valid outcome measure.  
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Abstract 
 
Purpose: 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography 
(FDG-PET) is a noninvasive imaging technique used clinically to detect 
malignant tumours. FDG-PET has been established as a tool for diagnosis 
of recurrent or metastatic colorectal carcinoma. Several case series suggest 
that FDG-PET also detects larger adenomas. The goal of this study was to 
investigate whether FDG-PET is able to detect colonic adenomas. 
Patients and Methods: FDG-PET was performed in 100 consecutive patients 
in whom colonic adenomas were suspected on barium enema (n=47) or 
sigmoidoscopy (n=53). A positive scan was defined as focal large bowel 
FDG accumulation. FDG-PET was followed in all cases by colonoscopy, and 
removed adenomas were examined histopathologically.  
Results: Colonoscopy confirmed the presence of adenomas in 68 of 100 
patients. In 35 patients, there was focal FDG accumulation at the site of the 
adenoma. The sensitivity of FDG-PET increased with adenoma size (21%, 
adenomas 1 to 5 mm; 47% 6 to 10 mm; and 72% > 11 mm). The sensitivity 
of FDG-PET also increased with the grade of dysplasia (33%, low grade; 
76%, high grade; and 89% carcinomas). The overall specificity was 84%. 
Conclusion: FDG-PET detects colonic adenomas and the diagnostic test 
characteristics improve with size and grade of dysplasia of the adenoma. 
 
 
Introduction 
 
Colorectal adenocarcinoma (CRC) is the second most common cause of 
cancer-related deaths in the Western world and the fourth most frequent 
malignancy (1;2). The most important indicator of outcome after surgical 
resection of CRC is the pathologic stage at presentation. This is reflected by 
a five-year survival of approximately 90% in stage I, 60 to 80% in stage II, 40 
tot 60% in stage III and 4% in stage IV (3). These data underscores the 
importance of diagnosing CRC in an early or premalignant stage.  
Colon carcinogenesis is regarded as a multifaceted process influenced by a 
variety of hereditary and lifestyle factors and involves a histologic 
progression from adenomatous polyps to colonic cancer (4;5). The incidence 
of adenomas increases with age, and the risk for malignancy with size. For 
example, malignant transformation is detected in only 1% of adenomas 
measuring < 1 cm, compared to 10% in larger adenomas (6;7). Indeed, 
detection and removal of adenomas is thought to result in a decrease in the 
incidence and mortality from colorectal cancer (8). A broad range of 
screening modalities for the detection of adenomas are available, such as 
fecal occult blood testing, endoscopy, barium enemas, and virtual 
colonoscopy. Although colonoscopy is regarded as the gold standard for the 
detection of premalignant lesions such as adenomatous polyps, it is not 
optimal in terms of examination performance, safety and patient acceptance, 
and this calls for a different diagnostic approach.  
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Recently, 2-fluoro [18-]-2-deoxyglucose positron emission tomography 
(FDG-PET) has been introduced in clinical practice for imaging of various 
malignancies. FDG-PET is a non-invasive, functional imaging technique, 
which uses the radiopharmaceutical FDG (9). It is clinically used to detect a 
wide variety of tumours including lymphoma, melanoma, lung cancer and 
colon cancer (10). Several studies indicate a potential role of whole-body 
FDG-PET for the detection of malignant lesions of the colon (11). Indeed, 
FDG-PET is probably superior to conventional abdominal computed 
tomography in the assessment of patients with recurrent and metastatic 
CRC, and is reimbursed under Medicare for the diagnosis, staging and 
restaging of CRC (12-14). 
The situation is less defined for premalignant colorectal disease. The results 
from two retrospective studies suggest that FDG-PET may detect colonic 
adenomas, but it is uncertain which factors affect the diagnostic ability of 
FDG-PET (15;16). Furthermore, focal uptake in the colon is frequently 
identified on whole body FDG-PET in patients studied for malignancies other 
than CRC, and the implications of these findings are unclear. These 
considerations stimulated us to design a prospective cohort study to 
establish the diagnostic test properties of FDG-PET in the detection of 
colonic adenomas and their clinical relevance using colonoscopy and 
histology as the gold standard.  
 
 
Patients and methods 
 
Patient population  
Between July 2001 and May 2004, we enrolled 100 consecutive Dutch adult 
patients who were referred to the endoscopy unit of the Department of 
Gastroenterology and Hepatology (Radboud University Nijmegen Medical 
Centre, the Netherlands) because of the suspicion of colonic polyp(s) on 
sigmoidoscopy or barium enema. The group consisted of 58 males and 42 
females, mean age being 62 (SD 11) years. Patients were excluded if they 
were known with active inflammatory bowel disease or diverticulitis, because 
those diseases could lead to false-positive FDG-PET. We also excluded 
patients with known or suspicion of cancer. Patients with diabetes mellitus 
were excluded if fasting glucose concentration exceeded 15 mmol/L, as high 
serum glucose levels are responsible for false-negative FDG-PET. The study 
was approved by the local ethical committee. Informed consent was 
obtained. 
   
FDG-PET imaging 
A dedicated PET-scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN) was 
used for data acquisition. The spatial resolution of the PET camera was 5 
mm. Before FDG injection, patients fasted for at least 6 hours. Intake of 
sugar free-liquids was permitted. Immediately before the procedure, the 
patients were hydrated with 500 ml of water.  
FDG-PET detects clinical relevant adenomas of the colon: a prospective study 
 
90 
 
One hour after intravenous injection of 200 to 220 MBq FDG (Mallinckrodt 
Medical, Petten, The Netherlands) and 12 mg furosemide, emission and 
transmission images of the abdomen were acquired (10 minutes per bed 
position). The images were corrected for attenuation and reconstructed 
using the ordered-subsets expectation maximization (OSEM) algorithm. The 
reconstructed images were displayed in coronal, transverse and sagittal 
planes. 
 
Interpretation    
For this study, FDG-PET scans were analyzed visually by one of the staff 
physicians from the Department of Nuclear Medicine (Radboud University 
Nijmegen Medical Centre) and then reviewed by one of us (W.J.G.O), 
unaware of the results of the original interpretation of the FDG-PET, other 
diagnostic tests or the final diagnosis. Results were judged to be abnormal if 
focal accumulation of the tracer was detected in the large bowel. If focal 
uptake was demonstrated, the uptake within the lesion was quantified by 
calculating the maximum and mean standard uptake value (SUV) according 
to the formula: (maximum or mean region of interest activity in mCi/mL) 
divided by (injected dose in mCi/patient’s weight in kg). Maximum or mean 
region of interest activity in mCi/mL, were derived from the calibrated activity 
measured in a manually drawn region of interest over the focal abnormalities 
(converting measured counts to accumulated activity in mCi) divided by the 
size of this region of interest (converting voxel size to volumes).  Diffuse 
bowel accumulation was interpreted as physiologic. Disagreements were 
resolved by consensus.  
   
Colonoscopy 
Flexible endoscopy procedures were performed after thorough oral lavage 
with Klean prep. The procedure was performed by a gastroenterology 
trainee directly supervised by an experienced gastroenterologist (F.M.N). 
The endoscopist was unaware of the result from FDG-PET. The coecum 
was reached in 97% of all procedures. All lesions appearing as possibly 
malignant were biopsied, and whenever possible, complete polypectomy 
was performed. If polypectomy was technically impossible, surgical resection 
was performed (n=3). All tissue specimens were immediately fixed in 10% 
buffered formalin solution before examination using haematoxylin and eosin 
staining. Each polyp was classified by an experienced pathologist as 
adenoma or other type polyp. Dysplasia was defined according to Vienna 
criteria as either low-grade dysplasia, high-grade dysplasia or carcinoma 
(17). The grade of dysplasia for each separate adenoma was recorded, and 
we scored the highest grade of dysplasia (low grade-high grade-carcinoma) 
in the adenoma for the purpose of the study. The results of colonoscopy 
were considered negative in case of normal mucosal findings or if polyps 
were hyperplastic on histopathologic examination. Colonoscopy results were 
considered positive when histopathology confirmed the presence of either 
adenomas or carcinomas.  
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The colonoscopic findings were reported in terms of the site and size of 
adenomas. Adenoma size was determined by endoscopical examination and 
data were verified by comparison with the data from macroscopical 
examination by the pathologists. In case of multiple polyps, we scored the 
largest adenoma. 
 
Experimental Procedures 
After diagnosis of the colonic adenoma by either diagnostic flexible 
sigmoidoscopy (n=53) or by double-contrast barium enema (n=47), patients 
were put on the waiting list for a therapeutic colonoscopy that included 
polypectomy. FDG-PET  was performed in the time-window between the 
diagnostic and therapeutic procedure. This study used colonoscopy as the 
gold standard, and patients were classified on the basis of their colonoscopic 
findings. 
 
Statistics 
Statistical analysis was performed with SAS statistical software, version 8.0. 
Data were described by means of frequency tables and descriptive statistics. 
The sensitivity was defined as the proportion patients with colonic polyps 
who actually had a positive FDG-PET. The specificity was defined as the 
proportion of patients without colonic polyps with a negative FDG-PET. The 
positive predictive value (PPV; the probability that the patient had colonic 
polyps when restricted to those patients who had a positive FDG-PET) was 
calculated as follows: true positive divided by true positive plus false 
positive. The negative predictive value (NPV; the probability that the patient 
will not have colonic polyps when restricted to all patients who had a 
negative FDG-PET) was defined as: true negative divided by true negative 
plus false negative. 
  
 
Results 
 
Detection of Presence of Adenomas 
In 100 patients in whom a previous sigmoidoscopy (n=53) or double contrast 
barium studies of the colon (n= 47) had shown lesions suggestive for colonic 
adenomas, colonoscopy detected adenomas in 68 patients, but failed to 
confirm the presence of an adenoma in the colon in 32 patients. In 18 of 32 
patients the preceding examination had been a double contrast barium 
study, whereas sigmoidoscopy had been the diagnostic tool for 14 of 32 
patients. Within the latter group, all adenomas detected were small and had 
already been completely removed by biopsy during the initial sigmoidoscopy. 
Histopathologic examination of removed lesions demonstrated hyperplastic 
polyps (n=4), adenomatous polyps (n=5), a lipoma (n=1), an inflammation 
polyp (n=1) and normal mucosa (n=3).  In all of these cases biopsy 
completely removed the lesion. 
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FDG-PET 
All 100 patients underwent an FDG-PET, and 40 patients had significant 
focal colonic FDG accumulation.  
 
Diagnostic Characteristics of FDG-PET as a Test for Detecting Colonic 
adenomas 
In 35 patients with a positive FDG-PET, colonoscopy showed a significant 
mucosal lesion. These lesions included carcinomas (n = 8), and adenomas 
with high-grade dysplasia (n = 13) and low-grade dysplasia (n = 14). The 
median size of the adenomas was 15 mm (range, 2 to 50 mm) and most 
adenomas were at least 15 mm (n = 21). The adenomas were predominantly 
located in the sigmoid (n = 26). The calculated mean and SD of the 
maximum SUV of this total group was 5.0 (range, 1.3 to 14.4). In all cases, 
FDG accumulation corresponded with the adenoma site. In 33 patients, 
FDG-PET failed to demonstrate colonic hotspots, but colonoscopy did detect 
significant abnormalities. Twenty-eight patients had adenomas with low-
grade dysplasia, whereas four patients had adenomas with high-grade 
dysplasia. In one patient, colonoscopy detected an 8 mm large tubular 
adenoma with histopathologic evidence for foci of invasive carcinoma that 
had been missed by PET. The median size of the adenomas was 6 mm 
(range, 2 to 30 mm), and almost all adenomas were smaller than 11 mm (n = 
23). 
Table 1 summarizes the FDG-PET results. FDG-PET is positive in 80% of 
larger adenomas, but negative in the large majority of small adenomas (1 to 
6 mm; p < .001). The sensitivity of FDG-PET increases with diameter of the 
polyp and rises from 21% for small (1 to 5 mm) polyps to 72% for larger (> 
11 mm) polyps. The specificity of FDG-PET was 84%. The sensitivity of 
FDG-PET was 33% for adenomas with low-grade dysplasia, 76% for 
adenomas with high grade dysplasia, and 89% for carcinomas (Table 2). For 
the detection of polyps, regardless of size and dysplastic grade, FDG-PET 
has a PPV of 88% and a NPV of 45%, which suggests that FDG-PET has a 
better accuracy for detecting the presence polyps rather than excluding its 
absence. When compared with the subgroup of patients without polyps, the 
detection of large (> 11 mm) adenomas yields a PPV of 82% and a NPV of 
75%. Likewise, for the detection of carcinoma, PPV is 61% while NPV is 
96%. These results in our study suggest that FDG-PET was not likely to 
miss colonic carcinoma and that an FDG-PET with negative results in most 
instances excluded the presence of colonic carcinoma.  
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Table 1 Summary of he diagnostic Characteristics of FDG-PET in the Detection of 
Colonic Adenomas of Various Size. 
 
    0-5 mm 6-10 mm ≥ 11 mm No polyp
    
PET correctly positive  4      8  23  0  
PET false positive  0      0  0  5  
PET correctly negative 0      0  0  27 
PET false negative  15      9  9      0 
 
 
Sensitivity, %   21    47  72  
Specificity, %         84 
   
Abbreviation: FDG-PET, 2-(18F)-fluoro-2-deoxy-D-glucose positron emission 
tomography. 
 
  
 
Table 2 Summary of the Diagnostic Characteristics of FDG-PET in the detection of  
Colonic Adenomas of Various Grades of Dysplasia 
 
     Grade of Dysplasia 
     
Low High Carcinoma  No polyp 
 
PET correctly positive  14 13 8   0 
PET false positive   0 0 0   5 
PET correctly negative  0 0 0   27 
PET false negative   28 4 1   0 
 
Sensitivity, %    33 76 89 
Specificity, %         84 
 
Abbreviation: FDG-PET, 2-(18F)-fluoro-2-deoxy-D-glucose positron emission  
tomography. 
 
 
Specificity 
In 27 patients, neither FDG-PET nor colonoscopy demonstrated any 
mucosal abnormality in the colon. There were five patients in whom PET 
demonstrated focal FDG accumulation in the large bowel, but in whom 
colonoscopy failed to reveal adenomas. In a single patient, colonoscopy was 
compatible with sigmoidal diverticulitis that correspond with localized FDG 
uptake at the same site. Four patients had a normal colonoscopy. The 
localization of false-positive hotspots was sigmoid (n = 2) and ascending 
colon (n = 2). In this group, the calculated average and standard deviation 
(SD) of the maximum SUV were 3.5 and 1.8, respectively. The site of the 
adenoma had no influence on the FDG-PET outcome (p = .46). 
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Discussion 
 
Our results show that FGD-PET detects premalignant colonic adenomas. 
The grade of dysplasia and size of the adenoma were clearly important 
discriminatory factors that predicted detection, while other parameters such 
as localisation of the adenoma, sex or age did not affect the results. We 
found that FDG-PET has sensitivity of 72% for the detection of larger (> 11 
mm) and of 76% for adenomas with high-grade dysplasia. The specificity 
was 84%, whereas for the detection of polyps (regardless of size or 
dysplastic grade) the PPV is 88% and the NPV 45%. Intensity of tracer 
uptake does not allow discrimination between adenomas (n = 27) and 
carcinomas (n = 8) as maximum SUVs (average, 5.9; SD, 3.7), respectively 
(average, 6.5; SD, 3.0) did not differ (18;19). 
Few retrospective studies suggest that detection of adenomas by FDG-PET 
is possible(15;16;19-21). In those studies, the adenoma size was the most 
important variable to predict outcome of FDG-PET, and the detection rate 
increased significantly with size of the adenoma. There are no studies on the 
effect of the grade of dysplasia on diagnostic performance of FDG-PET. In 
contrast to our results, one study suggested that localization matters (16). 
This study showed a higher detection rate in coecum, ascending and 
descending colon compared to the sigmoid and transverse colon (16).  
Significant shortcomings of these earlier studies is their cross-sectional 
nature, which makes them prone to positive selection. FDG-PET had been 
performed either for staging malignant disease other than CRC (20;21) or 
had been done as part of a cancer-screening program(16), and the detection 
of adenomas was merely coincidental. More importantly, colonoscopy had 
not been performed in all cases (20;21).  
We detected that a positive double-contrast barium enemas in 10 (21%) of 
47 patients was followed by a negative colonoscopy. These data are in 
agreement with the false-positive rate of barium enemas in The National 
Polyp Study (22). In eight false-positive barium enemas, FDG-PET was true-
negative. 
The PPV of FDG-PET was 88% which suggest that in 88% of the cases, 
colonic FDG accumulation accurately identifies an adenoma. One limitation 
of our finding is that the adenoma prevalence in our population (68%) was 
relatively high. It is possible that in a population with a lower prevalence of 
adenoma, the PPV of FDG-PET will decrease as the proportion of patients 
with false-positive tracer uptake may increase. False-positive results are an 
unwanted aspect of any diagnostic tool, and FDG-PET is no exception. In 
5% of our cases FDG-PET generated false-positive results and we were 
able to identify several important contributing factors. Normal accumulation 
in the colonic wall mucosa my appear focal and can be misinterpreted as 
clinically significant (nonphysiological) FDG accumulation. In our study, two 
patients were classified as false-positive, because colonoscopy failed to 
identify any mucosal abnormality despite focal FDG accumulation.  
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It is possible that colonoscopy missed a polyp, as back-to-back colonoscopy 
studies demonstrated a missing rate of 15% to 24% for (mostly small) 
adenomas (23;24). Further, we identified diverticulitis as a potential 
confounder. In these cases, FDG accumulation is most likely caused by 
uptake in inflammatory cells. 
Our study was designed to investigate the diagnostic ability of FDG-PET in 
detection of colonic adenomas. We aimed to include patients with lesions 
indicative of colonic polyps on sigmoidoscopy or barium enema. On 
histopathologic examination nine polyps were carcinomas,  FDG-PET 
detected all but a single 8-mm large polyp with histopathologic signs of 
invasive carcinoma. In addition, FDG-PET also missed three other clinical 
relevant large adenomas with high grade dysplasia. Given the overall NPV 
of 45% and the relatively high cost of FDG-PET, the procedure does not 
qualify as a screening modality for colonic adenomas because very small 
polyps and polyps with a low-grade of dysplasia are missed. Conversely, 
because of the high PPV (88%) of FDG-PET for clinically significant colonic 
adenomas, we feel that incidental identification of focal FDG accumulation 
necessitates follow-up by total colonoscopy. The timing of colonoscopy is, of 
course, determined by the nature and severity of the underlying disease that 
led to the initial request for FDG-PET. 
FDG-PET detects benign colonic adenomas, but the sensitivity of this test 
depends on the size and grade of dysplasia of the colonic adenoma, with the 
latter being the most important discriminative factor that predicts detection of 
the adenoma. Many dysplastic adenomas are missed by FDG-PET 
(especially when small and with low-grade dysplasia), which is one of the 
factors limiting its utility as a screening modality for adenomas. 
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Abstract 
 
Purpose: Autosomal dominant hereditary diffuse gastric cancer (HDGC) is 
caused by germ-line E-cadherin (CDH1) gene mutations. Early detection of 
cancer in carriers is difficult because HDGC escapes endoscopic detection. 
We hypothesized that the glucose metabolism is enhanced in HDGC and 
that this can be detected with [18F]fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET).  
Experimental Design and Results: An asymptomatic twenty-eight year-old 
female was seen at our outpatient clinic because of a request for screening 
on HDGC. Her father and younger sister died of diffuse gastric cancer, at the 
ages of 52 and 27, respectively. Mutational analysis of the CDH1 gene in 
this patient demonstrated a novel heterozygous splice-site mutation in exon 
8 (1135delACGGTAATinsTTAGA). Upper gastrointestinal endoscopies 
revealed no macroscopic abnormalities, but one of the 40 random biopsy 
specimens showed well-differentiated signet-cell carcinoma. A FDG-PET 
scan demonstrated two spots of FDG accumulation, one located in the 
proximal part of the stomach and the second in the region of the pylorus. A 
total gastrectomy was performed and microscopic examination showed focal 
localization of intramucosal adenocarcinoma of the signet-cell type in the 
cardiac and antrum area. Most notably, the localization of the FDG 
accumulation matched the localization of the carcinoma. 
Conclusions: We present an asymptomatic patient from a HDGC family 
carrying a novel CDH1 mutation in whom FDG-PET scanning facilitated 
early detection of HDGC. This calls for further investigation of the role of 
FDG-PET scan as a screening modality in HDGC. 
 
 
Introduction 
 
Gastric cancer is a particularly common gastrointestinal malignancy and has 
an incidence rate of 9/100.000 in the United States (1).  Some 10% of the 
gastric cancer cases show familial clustering (2;3), and a subgroup of these 
patients suffer from hereditary diffuse gastric cancer (HDGC; Mendelian 
inheritence in Man no.192090; http://www.ncbi.nlm.nih.gov/entrez/ 
dispomim.cgi?id=192090 ). This is an autosomal dominantly inherited 
disorder with about 70% penetrance (4). Until now, up to 80 HDGC families 
have been described (5;6). Approximately one third of these families carry a 
germ-line E-Cadherin (CDH1) gene mutation (7;8). CDH1 is localized on 
chromosome 16q22.1 and encodes for cadherin-1. This protein comprises 
five extracellular cadherin repeats, a transmembrane region, and a highly 
conserved cytoplasmic tail and functions as a calcium-dependent cell-cell 
adhesion glycoprotein. It is postulated that CDH1 acts as a tumour 
suppressor gene, and loss of function leads to development and progression 
of cancer by increasing proliferation, invasion, and/or metastasis.  
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The estimated cumulative lifetime risk of gastric cancer in CDH1 families is 
very high. It has been estimated that by age of 80 years, 67% of the males 
and 83% of females will have developed gastric cancer (4). The average age 
of onset of gastric cancer in CDH1 families is 38 years, but HDGC has been 
documented in teens as well (7;9). The pathology of HDGC is that of a 
poorly differentiated isolated-cell-type carcinoma with signet-cells. Clinically, 
it is characterized by individual cells infiltrating and thickening the gastric 
wall, without substantially formation of tumour mass. The infiltration results in 
a loss of distensibility of the wall of the stomach, and, because the individual 
signet-cells spreads submucosally, it may evade detection by endoscopy. 
This eliminates endoscopy as an effective screening tool in a population that 
would benefit most from early detection of a malignant disease. However, 
because most malignant cells demonstrate a high glucose uptake, this 
opens an avenue for another screening tool: [18F]fluoro-2-deoxyglucose 
positron emission tomography (FDG-PET) (10-14). FDG-PET is a 
noninvasive imaging technique that visualizes the glucose metabolism in the 
human body. Before the PET procedure, patients fast for at least 6 hours to 
suppress the glucose and insulin level. FDG is injected, serum glucose level 
is measured, and 1 hour later, the scanning starts. FDG is a glucose analog, 
and it uses glucose transport receptors (GLUT-1) to enter the cell (10). 
Similarly to glucose, FDG, is phosphorylated by hexokinase to FDG-6-
phosphate. In contrast to glucose-6-phosphate, FDG-6-phosphate, is not 
further metabolized; and, because it cannot transfer beyond the cell 
membrane, it is trapped in the cell. Most malignant cells demonstrate high 
FDG uptake because of increased expression of the GLUT-1 receptor on the 
cell membrane. In addition, a high enzymatic activity of hexokinase and low 
levels of glucose-6-phosphatase in tumour cells also account for an elevated 
FDG uptake. The great advantage of FDG-PET over conventional radio-
diagnostic methods lies in its ability to visualize metabolic activity of the 
tumour rather than mere anatomical borders. We examined whether FDG-
PET scanning is able to detect early gastric cancer in HDGC. 
 
 
Methods and results 
 
A twenty-eight year-old female was seen at our outpatient clinic because of 
a request for screening on hereditary gastric cancer. She had no physical 
complaints, but her family history was strongly positive for gastric cancer. 
Her father died, at the age of  52 years, of diffuse gastric cancer, signet-cell 
type. Her (younger) sister was diagnosed with metastatic gastric cancer at 
27 years of age and died 10 months after diagnosis. A brother of her 
paternal grandfather also died at the age of 55 years of gastric cancer. In her 
nuclear family, two other sisters and her mother were not known to have 
gastric cancer.  
Because we suspected hereditary gastric cancer, we proceeded to perform 
mutation analysis of all 16 exons of the CDH1 gene.  
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In view of the unsettling family history, we performed endoscopic screening 
in parallel. The first upper gastrointestinal endoscopy showed macro-
scopically normal mucosa. We took 40 (at random) biopsy specimen from all 
parts of the stomach. Histopathological examination revealed normal gastric 
mucosa, without signs of inflammation, dysplasia or helicobacter pylori 
infection. Because of the possibility of sampling error, we went on to perform 
a second gastroscopy. Again no macroscopic abnormalities were noted, but 
now we detected well-differentiated adenocarcinoma of the signet-cell type 
in a single biopsy specimen taken from the fundus (Fig. 1). The diagnosis, 
diffuse gastric cancer, was made. 
 
 
Figure 1 
 
 
 
High-magnification (x400) H&E-stained image of loose epithelial cells in the lamina 
propria of the gastric mucosa. The cells are only partially typical signet-ring cells. On 
immunohistochemical examination, they were proved to be epithelial (keratin-
positive, CD68-negative). 
 
 
 
Pre-operative examination by computed tomography of the chest and 
abdomen showed no signs of metastasis. FDG-PET demonstrated two 
hotspots, one located in the proximal part of the stomach and the second in 
the region of the pylorus (Fig. 2). No other hotspots were seen elsewhere in 
the body. A total gastrectomy with Roux-en-Y-esophagojejunostomy was 
performed. The gastrectomy specimen was normal in appearance and by 
palpation. Microscopic examination of the complete mucosa showed in the 
cardiac and antrum area of the stomach focal localization of intramucosal 
adenocarcinoma of the signet-cell type. The localization of the FDG 
accumulation matched the localization of the carcinoma. On immuno-
histochemical staining, the tumour cells showed no GLUT-1 expression. 
Resection areas were free of tumour cells.  
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All 19 lymph nodes examined were negative for cancer. The carcinoma was 
classified as T1N0Mx. There was no need for adjuvant therapy. 
Results of genetic analysis of this patient has been documented recently 
(15) and DNA sequencing revealed a hitherto undescribed splice site 
mutation in exon 8 of CDH1, with the deletion of 8 bp and the insertion of 5 
other bp. (1135delACGGTAATinsTTAGA). This mutation causes a truncated 
protein with removal of the highly conserved cytoplasmic region (amino acid 
732-879). 
One year after surgery, there are no signs of recurrence or metastases. 
 
 
Figure 2 
 
 
 
Serial coronal sections (front to back) of FDG-PET in our patient; diffusely increased 
accumulation of FDG in the proximal part of the stomach and hotspot (arrows) in the 
region of the pylorus of the stomach. 
 
 
 
Discussion 
 
This case demonstrates that CDH1 mutations are associated with early-
onset HDGC. The heterozygous germ-line CDH1 mutation will most probably 
cause a 50% reduction in E-cadherin function, and, although this may be 
sufficient to develop HDGC, it is likely that inactivation of the wild-type allele 
is needed to enable tumour progression. The “second-hit” in most of the 
cases is due to hypermethylation of the CDH1 gene promoter, (16) loss of 
heterozygosity, or somatic mutations, but none of these were detected in 
tumour material of our patient (15).  
Although, the overwhelming majority (26 of 30) of germ-line mutations 
characterized, thus far, are associated with HDGC, (6) CDH1 mutations 
have also been implicated in breast, colorectal, thyroid and ovarian cancer 
(5). The consequences for the clinical follow-up of our patient with regard to 
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the development of other malignant diseases, such as breast cancer, are still 
under discussion.  
Present guidelines emphasize the importance of intensive clinical sur-
veillance of germ-line CDH1 mutation carriers. Regular endoscopy with 
multiple biopsies (every 6-12 months) has been recommended as the most 
optimal method for early detection of gastric cancer in HDGC families (17). 
However, mucosal abnormalities can be absent despite the presence of 
(sometimes) extensively spread malignancy. This calls for another screening 
modality, and as illustrated by our case report, the FDG-PET scan was able 
to detect HDGC in an early phase, leaving room for curation. This illustrates 
the high sensitivity of the screening technique, because histopathological 
examination demonstrated only a minor tumour load. In current gastro-
enterological practice, FDG-PET is most commonly used to stage 
esophageal carcinoma, to detect and stage recurrence of colorectal 
carcinoma and to differentiate between benign and malignant pancreatic 
lesions (18-21). Experience with this technique in patients with gastric 
carcinoma is very limited. Most of the studies focused on recurrent gastric 
cancer or locally advanced disease (22-25). They all found a low sensitivity 
and specificity to detect recurrence or locally advanced disease, with figures 
around 70%. Most notably, in subgroup analysis, the sensitivity in signet-cell 
gastric carcinoma is even worse; it differs between 40 (23) and 60% (22). 
Moreover, there appears to be a significant lower uptake of FDG in signet-
cell carcinoma (24) compared with well- or moderate differentiated 
adenocarcinomas. These findings are in line with experimental data showing 
that, in gastric carcinoma, GLUT-1 is expressed late in carcinogenesis and 
that signet-ring-cell carcinomas rarely express GLUT-1 (26). This accords 
with the absence of GLUT-1 expression on immunohistochemical staining of 
gastric carcinoma specimens. This suggests that other mechanisms, such as 
elevated hexokinase levels or decreased activity of glucose-6-phosphatase, 
lead to high FDG uptake in HDGC. However, apart from a late expression of 
GLUT-1, still little is known about FDG accumulation in gastric cancer. It is 
also possible that HDGC stands apart from isolated gastric cancer in that 
these signet cells might overexpress other GLUT receptors, such as GLUT- 
2 and -3, which facilitate the accumulation of FDG.   
In view of the grave prognosis of HDGC, prophylactic gastrectomy has been 
recommended for asymptomatic CDH1 mutation carriers. This probably 
leads to a better survival of these patients. For example, in two small series 
of five patients, foci of diffuse gastric cancer were identified in all, despite 
negative endoscopic screening (27;28). However, there is a trade-off 
because surgery is accompanied by a mortality rate of 1 to 2% and a 
considerable morbidity such as persistent dumping symptoms (29). 
Furthermore, the timing of gastrectomy in mutation carriers is under debate. 
This case suggests that FDG-PET scanning can aid in the decision about 
timing of surgery. In conclusion; HDGC is caused by mutations in CDH1, and 
most symptomatic patients present in an incurable stage. 
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We present a case with some striking features: (a) early detection by 
endoscopic screening; (b) a novel CDH1 mutation; and (c) identification of 
the tumour by FDG-PET scanning in a very early stage. Our data suggest 
that FDG-PET scanning can have a place as a screening tool in HDGC 
and/or might have a role in timing of the gastrectomy. Further investigation is 
warranted to determine the role of FDG-PET in HDGC and to identify the 
mechanism of high FDG uptake in this specific syndrome. 
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As outlined before, this thesis aimed to study the diagnostic ability of FDG-
PET to detect premalignant disorders and early cancers in the 
gastrointestinal tract. To investigate our hypothesis we designed clinical as 
well as preclinical experimental studies. This summary focuses on the 
discussion of the results of our studies. In addition, we highlight the, 
implications of the results in respect of future FDG-PET research. 
 
 
Pancreas 
 
Chapters 3 and 4 focused on pancreatic diseases. Recent (surgical) pu-
blications showed that FDG-PET has a sensitivity between 68-100% in 
detecting pancreatic carcinoma. Our study (chapter 4) was focused on 
patients with CP, first because of their increased risk on pancreatic 
carcinoma (especially those with hereditary CP) and moreover because of 
the lack of diagnostic abilities to detect pancreatic carcinoma in these 
patients. We performed FDG-PET in 77 CP patients, 6 patients with CA 
superimposed on CP, and we included 26 CA patients as a positive control. 
Our results show that FDG-PET can detect pancreatic carcinoma in CP 
patients (83%). On the other hand, in CP patients without cancer FDG-PET 
is negative in the large majority of patients (87%). These two results jointly 
suggest that FDG-PET can be used as a screening modality for pancreatic 
cancer in CP patients. Our BOP hamster study (chapter 3) seems to 
corroborate with this hypothesis. The BOP hamster study was mainly 
designed to investigate the dynamics of FDG accumulation in pancreata, 
especially in those with pancreatic cancer. Sixty hamsters were injected with 
BOP, autopsy took place in groups of five hamsters. Pancreata were 
examined histopathological and FDG accumulation was determined. We 
showed that FDG gradually accumulates in pancreata with cancer. The FDG 
accumulation precedes histopathological development of cancer. These data 
suggest that the moment of detection of pancreatic abnormalities associated 
with pancreatic cancer, with FDG-PET can be done at the premalignant, 
stage. This creates new opportunities for early detection of pancreatic 
cancer and screening of the high-risk population such as patients with 
hereditary CP. 
As a result of the facts stated above, a positive FDG-PET scan in CP 
patients should lead to extensive examinations to prove or exclude 
pancreatic cancer. 
 
 
Colon 
 
Chapters 6 and 7 deal with premalignant abnormalities in the colon, colonic 
adenomas. We studied (chapter 7) 100 patients with suspicion on colonic 
adenomas on barium enema or sigmoidoscopy. All patients underwent first 
FDG-PET followed by a total colonoscopy with polypectomy.  
                                                                            Chapter 8 
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In this study we showed that FDG-PET is able to detect colonic adenomas 
(overall sensitivity 51%). The sensitivity of FDG-PET increased with size of 
the polyp and grade of dysplasia (chapter 7 table 1 and 2). We detected that 
the dysplasia grade is the most important factor that determines detection by 
FDG-PET. The overall specificity of FDG-PET in the detection of colonic 
adenomas was 84%. We also showed that, in this specific population with a 
high prevalence of colonic adenomas, FDG-PET had a high positive 
predictive value (88%). In contrast to the high PPV, the negative predictive 
value was rather low. Our final conclusion derived from this study is that 
FDG-PET cannot be used as a screening modality for colonic adenomas 
(considering the low NPV), but we feel that a focal hotspot in the large bowel 
on FDG-PET should be followed by total colonoscopy. 
In an experimental model for colon carcinoma (AOM treated rats) (chapter 6) 
we correlated histopathology with FDG accumulation in adenomas. Seventy 
rats were treated with AOM and sacrificed at regular intervals, FDG uptake 
was measured and correlated with histopathology. Unfortunately, the rats 
developed only a small number of adenomas and mostly in combination with 
carcinomas. In line with the clinical study there is a significant increase in 
FDG accumulation in adenocarcinomas in rats, and also a higher FDG 
uptake in adenomas. A type 2 error precluded meaningful statistical ap-
praisal and due to the small number of solitaire adenomas no correlation 
could be made between FDG accumulation and dysplasia grade.  
 
 
(Pre) malignant disorders and early cancer 
 
Chapter 5 describes FDG-PET in FAP patients. This group of patients has 
multiple adenomas and a significant increased risk on multiple cancers, 
particularly CRC and duodenal carcinoma. FDG-PET was performed in 24 
FAP patients and during the same time span a duodenal endoscopy was 
done. In 19 patients focal FDG accumulation was absent and this includes 6 
patients with advanced duodenal adenomas with high-grade dysplasia. In 
five patients FDG-PET revealed focal uptake, specifically two with duodenal 
carcinomas, one with metastases of a pouch carcinoma, one sclerosing 
haemangioma and one false-positive scan. The most important observation 
stems from a patient with a hotspot on FDG-PET 2 years prior to the 
histopathological diagnosis of duodenal adenocarcinoma. In hindsight we 
speculate that at the time of the first FDG-PET this patient already had a 
duodenal adenocarcinoma. However, histopathology demonstrated only 
high-grade dysplasia, most likely due to sampling error. Also, in view of the 
fact that other large adenomas with high-grade dysplasia showed no hotspot 
on FDG-PET. Considering the relative long survival (3 years) and the 
absence of signs of invasion of malignancy on CT and endosonography (on 
the moment of first positive FDG-PET) it had to be an early duodenal 
carcinoma. These data suggest that FDG-PET is able to detect early 
duodenal cancer in FAP patients. 
Summary, General discussion and Conclusion 
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Lastly we demonstrate a case in which FDG-PET detects early gastric 
carcinoma in an asymptomatic E-cadherin mutation carrier in a HDGC family 
(appendix) This is a very important observation, because gastric cancer in 
HDGC patients is very difficult to detect, mostly  because of lack of tumour 
mass. In most symptomatic cases, there is a matter of advanced disease 
precluding curation. Prophylactic gastrectomy is recommended for a-
symptomatic CDH1 mutation carriers. The recommendations are even more 
difficult in families in which the mutation is not yet known. It is possible that 
FDG-PET can acquire a place in timing of gastrectomy or even prevent 
gastrectomy in families with an unknown mutation. More studies are 
warranted to investigate the exact diagnostic abilities of FGD-PET in this 
specific disease. 
 
From this thesis we conclude that FDG-PET is able to (I) detect pancreatic 
cancer superimposed on CP, (II) differentiate between CP and pancreas-
carcinoma, (III) detect benign colonic adenomas, (IV) detect (early) duodenal 
cancer in FAP patients, (V) detect early gastric cancer in an asymptomatic 
E-cadherin mutation carrier. 
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In dit proefschrift werden de diagnostische mogelijkheden van FDG-PET met 
betrekking tot het opsporen van premaligne afwijkingen en vroeg 
carcinomen in het maag-darmkanaal onderzocht. Hoofdstuk 1 is een 
algemene inleiding tevens worden hierin de studies beschreven welke 
ontwikkeld zijn om onze hypothesen te onderzoeken. In hoofdstuk 2 worden 
de huidige toepassingen van FDG-PET binnen de gastroenterologie 
beschreven. In deze samenvatting zullen de resultaten van de studies 
geïntegreerd worden bediscussieerd.  
 
 
Pancreas  
 
In de hoofdstukken 3 en 4 ligt de nadruk op de pancreas. Recente, met 
name chirurgische literatuur, toont dat FDG-PET een sensitiviteit heeft 
tussen de 68-100% voor het aantonen van pancreascarcinoom. In onze 
klinische studie (hoofdstuk 4) hebben we het accent gelegd op patiënten 
bekend met chronische pancreatitis (CP), ten eerste omdat deze groep 
patiënten een duidelijk verhoogd risico heeft op het ontwikkelen van een 
pancreas-carcinoom (vooral de groep met hereditaire pancreatitis) en meer 
nog omdat het detecteren van een pancreascarcinoom, in deze groep 
patiënten, met de huidige diagnostische mogelijkheden uitermate moeilijk is. 
FDG-PET werd verricht bij 77 CP patiënten, 6 patiënten met een carcinoom 
bij een bekende CP, en 26 met een pancreascarcinoom. Deze 
pancreascarcinoom patiënten dienden als positieve controle. In onze serie 
blijkt FDG-PET in staat om pancreascarcinoom te detecteren in 83% van de 
CP patiënten. Aan de andere kant, FDG-PET blijft negatief in het grootste 
deel van de CP patiënten zonder carcinoom (87%). Samen suggereren deze 
twee resultaten dat FDG-PET  gebruikt kan worden als een 
screeningsmodaliteit voor pancreascarcinoom in de groep chronische 
pancreatitis patiënten. Onze BOP hamster studie (hoofdstuk 3) lijkt deze 
hypothese te ondersteunen. De BOP  hamster studie was voornamelijk 
ontworpen om de dynamiek van de FDG stapeling in de pancreas van de 
hamster te bestuderen en dan vooral in de hamsters welke 
pancreascarcinoom ontwikkelden. Zestig hamsters werden behandeld met 
BOP en in groepen van 5 hamsters op vooraf bepaalde tijdstippen, geofferd. 
De pancreata werden histologisch, onderzocht en de FDG opname werd 
bepaald. In pancreata met kanker blijkt de FDG opname gradueel te stijgen. 
Deze FDG stijging is al aanwezig voordat er histologisch daadwerkelijk 
sprake is van kanker. Deze waarneming suggereert dat met FDG-PET 
pancreascarcinoom al in een premaligne fase kan worden opgespoord. Dit 
creëert nieuwe mogelijkheden voor vroeg detectie en, screening van hoog 
risico groepen, zoals patiënten met hereditaire pancreatitis. Uit de 
bovenstaande resultaten vloeit voort dat een positieve FDG-PET scan bij 
patiënten met CP moet leiden tot uitgebreide aanvullende diagnostiek om 
een pancreascarcinoom aan te tonen, danwel uit te sluiten.  
 
                                                                            Chapter 9 
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Colon 
 
Hoofdstuk 6 en 7 behandelen premaligne afwijkingen in het colon, de colon 
adenomen. We hebben een onderzoek opgezet met 100 patiënten met 
verdenking op een dikke darm poliep bij ofwel een dikke darm foto danwel 
bij een sigmoidoscopie. Allereerst ondergingen de patiënten een FDG-PET 
scan nadien volgde een volledige coloscopie met het verwijderen van de 
poliep. In deze studie tonen we aan dat FDG-PET in staat is om 
goedaardige adenomen op te sporen (overal sensitiviteit is 51%). De 
sensitiviteit neemt toe naar mate de poliep groter is en naar mate de 
histologie ernstigere dysplasie toont (hoofdstuk 7 tabel 1 en 2). De dysplasie 
graad blijkt de belangrijkste discriminerende factor met betrekking tot het al 
of niet detecteren van de poliepen. De overal specificiteit van FDG-PET  in 
onze studie was 84%. In onze specifieke patiënten populatie met een hoge 
adenoom prevalentie heeft FDG-PET een hoge positief voorspellende 
waarde, namelijk 88%. Contrasterend tot de hoge positief voorspellende 
waarde blijkt de negatief voorspellende waarde behoorlijk laag, 45%. Gezien 
deze lage negatief voorspellende waarde is FDG-PET helaas niet te 
gebruiken als een screenings modaliteit voor colon adenomen, wel vinden 
wij dat indien er een hotspot in het colon wordt gevonden bij FDG-PET er 
een volledige coloscopie verricht dient te worden. 
In ons dierexperimentiele colon adenoom/carcinoom studie (AOM ratten 
studie) (hoofdstuk 6) correleerden we de histopathologie met de FDG 
opname in de adenomen. Zeventig ratten werden behandeld met AOM en 
geofferd op vaste tijdstippen, de FDG opname in de adenomen werd 
gemeten en vergeleken met de histopathologie. Helaas ontwikkelden de 
ratten slechts weinig adenomen en meestal waren er bij dezelfde ratten ook 
carcinomen aanwezig. Net als in de klinische studie was er in de 
adenocarcinomen een significante stijging van FDG opname aanwezig, 
tevens toonden de adenomen ook een verhoogde FDG opname, maar lager 
dan bij de carcinomen. Helaas bleek gezien de kleine aantallen solitaire 
adenomen een correlatie tussen de dysplasie graad en de FDG opname 
onmogelijk. 
 
 
(Pre)maligne aandoeningen en vroeg-carcinomen 
 
Hoofdstuk 5 beschrijft FDG-PET bij FAP patiënten. Deze patiënten groep 
heeft multipele adenomen en een sterk verhoogd risico op het ontwikkelen 
van carcinomen, met name colorectaal carcinoom en duodenum carcinoom. 
Bij 24 patiënten werd een FDG-PET scan verricht met aanvullend in 
dezelfde periode een gastroduodenoscopie.  FDG-PET toonde geen 
afwijkingen bij 19 patiënten, deze groep bevatte 6 patiënten met uitgebreide 
duodenum adenomen met hooggradige dysplasie. Vijf maal was er sprake 
van pathologisch verhoogde FDG opname, gelokaliseerd in tweemaal een 
duodenumcarcinoom, eenmaal een scleroserend hemangioom, een patiënt 
Samenvatting en conclusies 
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met metastasen van een pouch carcinoom en de laatste was een vals- 
positieve scan.  
De belangrijkste observatie van deze studie was een patiënt met een 
positieve FDG-PET 2 jaar voor de histologische diagnose duodenum 
adenocarcinoom werd gesteld. Waarschijnlijk was er op het moment van de 
positieve FDG-PET al sprake van een carcinoom, histopathologie toonde 
toen slechts hoog-gradige dysplasie, vermoedelijk is er sprake geweest van 
sampling error. Zeker ook gezien het feit dat de overige duodenum 
adenomen met hoog-gradige dysplasie FDG-PET negatief waren. Gezien de 
relatief lange overleving (3 jaar) en de afwezigheid van weefsel invasie op 
de computer tomografie en endo-echografie (verricht ten tijde van de eerste 
positieve FDG-PET scan) was er op dat moment zeer waarschijnlijk sprake 
van een vroeg carcinoom. Deze data suggereren dat FDG-PET in staat is 
om vroege duodenum carcinomen bij FAP patiënten op te sporen. 
Tenslotte demonstreren we een casus waarin FDG-PET een vroeg 
maagcarcinoom ontdekt (appendix bij een asymptomatische E-cadherin 
mutatie drager binnen een HDGC familie. Dit is een zeer interessante 
bevinding, omdat het maagcarcinoom in het kader van HDGC erg moeilijk te 
diagnosticeren is, vanwege het ontbreken van tumor massa. Indien de 
patiënt wel symptomatisch is op het moment van diagnose, is er bijna altijd 
sprake van gemetastaseerde, incurable ziekte. Profylactische gastrectomie 
wordt aanbevolen voor CDH1 mutatie dragers. In veel families is de mutatie 
echter nog niet ontdekt, de aanbevelingen ten aanzien van gastrectomie zijn 
in deze families nog moeilijker. FDG-PET zou een plaats kunnen krijgen in 
de timing van gastrectomie, met name in de families waar de mutatie nog 
niet bekend is. Er zijn natuurlijk meer studies nodig om de exacte 
diagnostische mogelijkheden van FDG-PET in deze specifieke patiënten 
groep te bepalen.  
 
Uit dit proefschrift mogen we concluderen dat FDG-PET in staat is om (I) 
pancreascarcinoom bij chronische pancreatitis patiënten te detecteren, (II) te 
differentiëren tussen chronische pancreatitis en pancreascarcinoom, (III) 
benigne colon adenomen op te sporen, (IV) (vroege) duodenum carcinomen 
bij FAP patiënten aan te tonen, (V) vroeg maagcarcinoom op te sporen in 
een asymptomatische E-Cadherin mutatie drager.  
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[18F]FDG-PET   Two-(18F)-fluoro-2-deoxy-D-glucose positron                   
                                                  emission tomography 
FDG two(18F)-fluoro-2-deoxy-D-glucose 
CP  Chronic pancreatitis 
FAP Familial adenomatous polyposis 
BOP N-nitrosobis(2-oxopropyl)amine 
AOM Azoxymethane 
CRC Colorectal cancer 
HDGC Hereditary diffuse gastric cancer 
CT Computed tomography  
EUS  Endoscopic ultrasound  
GLUT-1  Glucose transport receptors 
SUV Standardized uptake value 
MRI Magnetic resonance imaging 
CEA  Carcino-embryonic antigen 
GIST Gastrointestinal  Stroma Cell Tumour 
PC  Pancreatic cancer 
PET Positron emission tomography  
%ID/g Perentage of the injected dose per gram 
tissue 
H&E Haematoxylin and Eosin 
r2 Correlation coefficient 
                                                                         Chapter 10 
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CP + CA Chronic pancreatitis complicated by 
pancreatic carcinoma 
ERCP Endoscopic retrograde 
cholangiopancreaticography 
TPS Tissue polypeptide specific antigen 
MRCP  Magnetic resonance 
cholangiopancreatography  
HCP     Hereditary chronic pancreatitis  
ACP    Alcohol induced chronic pancreatitis 
ICP     Idiopathic chronic pancreatitis 
OSEM    Ordered-subsets expectation maximization 
NPV    Negative predictive value 
PPV      Positive predictive value 
CBD    Common bile duct  
APC     Adenomatous polyposis coli 
IPAA     Ileo pouch anal anastomosis  
NPV    Negative predictive value 
PPV      Positive predictive value 
SD     Standard deviation 
CDH1    Germline E-cadherin gene mutation 
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Dankwoord 
 
Dit onderzoek heb ik gelukkig niet alleen gedaan. Ik wil mijn proefschrift 
eindigen met het bedanken van iedereen die mij geholpen heeft dit 
proefschrift en mijn promotie mogelijk te maken. Een aantal mensen zou ik 
graag in het bijzonder willen noemen. 
 
Allereerst de patiënten, die bereidwillig zijn geweest om geheel belangeloos 
een PET scan te laten verrichten. Zonder hen was er überhaupt geen 
proefschrift geweest. Dank hiervoor. 
 
Prof. dr. J.P.H. Drenth, beste Joost, het is dan toch zover gekomen, ik voel 
me vereerd jouw eerste promovendus te zijn! Ik dank je voor het vertrouwen 
dat je, ondanks de tegenslagen, altijd in mij hebt gehad en mij hebt weten te 
motiveren mijn proefschrift tot een goed einde te brengen. Wij hebben 
ontzettend veel mail contact gehad om dit  proefschrift te verwezenlijken; 
Nijmegen-Nijmegen, Washington-Nijmegen, Breda-Nijmegen, jouw antwoord 
op mijn mails waren bijna altijd “per kerende post”. Vaak hoopte ik dat jouw 
antwoord even op zich liet wachten, zodat ik even “rust” had. De snelheid 
van jouw mails illustreert het tempo waarmee je onderzoek doet en nieuwe 
experimenten opzet. Ik heb onze gesprekken over mijn onderzoek als erg 
stimulerend en verhelderend ervaren, het gaf me steeds weer nieuw zicht op 
onze onderzoeksresultaten. Ik herinner me vooral het weekend in 
Washington, voor mij werd in dat weekend veel duidelijk over hoe een artikel 
geschreven dient te worden. Behalve aan het wetenschappelijke doel had je 
in dat weekend ook uitgebreid gedacht aan het sociale programma, wat, 
naar mijn mening, ook tekenend is voor jou. Joost, bedankt! 
 
Prof. dr. W.J.G. Oyen, beste Wim, ik wil je bedanken voor het feit dat je altijd 
tijd had om even te brainstormen over de volgende stap in mijn onderzoek, 
ik heb dat als zeer inspirerend ervaren. Verder was je een snelle leverancier 
van foto’s voor de artikelen. 
 
Dr. F.M. Nagengast, beste Fokko, vooral jouw overzicht over de materie, de 
klinische relevantie ervan en het promoveren op zich vond ik erg 
verhelderend. Tevens zijn de ideeën voor de artikelen voor een belangrijk 
deel  van jou afkomstig geweest. Daarnaast wil ik je bedanken voor jouw 
belangrijke aandeel in mijn opleiding tot MDL-arts, ik verheug me op onze 
samenwerking in de toekomst. 
 
Prof. dr. J.B.M.J. Jansen, beste Jan, als hoofd van de afdeling heb je met 
name een aandeel gehad in de pancreatitis artikelen, vanuit deze positie 
waren jouw kritische opmerkingen erg behulpzaam.   
 
Prof. dr. J.H.J.M. van Krieken, beste Han, ik dank je voor het feit dat je 
ondanks al je drukke bezigheden tijd voor mij hebt weten vrij te maken. Met 
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name de avonden dat we samen over de microscoop gebogen de hamster 
preparaten zaten te bekijken en ons verwonderden over de niet eerder 
beschreven afwijkingen vond ik erg leerzaam en leuk. Ik denk echter niet dat 
ik in de toekomst het MDL-vak voor de pathologie zal verruilen….. 
 
“De heren van de PET scan”, jullie waren altijd bereid om voor mijn studie 
patiënten op korte termijn een PET-scan afspraak te plannen, zelfs als daar 
andere patiënten voor moesten worden verplaatst. 
 
Peter, je hebt me uitstekend geholpen en ingewijd in de dierexperimenten. 
Het was voor mij een geheel nieuwe ervaring om onderzoek te doen met 
hamsters en ratten.  
Verder wil ik Gerry, Bianca en Hennie van het dierenlaboratorium bedanken 
voor de zorg voor onze hamsters en ratten en het inspuiten van de 
onderzoeksstof.  
Juliette, bedankt voor de overname van de dierexperimenten op de 
momenten dat ik klinisch werk moest doen. 
 
Mijn collega’s van de MDL-afdeling, die bereid zijn geweest om een deel van 
het klinisch werk over te nemen, zodat er voor mij wat tijd vrij kwam om aan 
mijn onderzoek te besteden.  
 
Natuurlijk wil ook alle medeauteurs bedanken voor hun bijdrage aan de 
betreffende artikelen. 
 
Ik wil mijn familie, vrienden en volleybal team bedanken voor alle gezellige 
en ontspannende momenten! 
 
En natuurlijk mijn ouders, lieve papa en mama, ik dank jullie voor de 
onvoorwaardelijke steun en liefde.  
Tot slot, lieve Marcel, je hebt me altijd gestimuleerd om mijn proefschrift af te 
maken, vooral in de laatste fase waarin andere bezigheden (lees: het 
nieuwe huis verven) veel aantrekkelijker waren.  
Ik hoop dat wij, als straks de rust weer een beetje is teruggekeerd (na 
Breda, promoveren en verhuizen), samen een mooie tijd tegemoet gaan! 
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